[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fbmaKAsGoh0Ew3biXvvPyGBIbRgWG-LtL6tJnA4e6moY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"University Hospitals Cleveland Medical Center",[4],286,false,47,23,374132,15,174,[14,17,20,22,25,28,30,32],{"name":15,"count":16},"Bipolar Disorder",20,{"name":18,"count":19},"Sickle Cell Disease",8,{"name":21,"count":19},"Cystic Fibrosis",{"name":23,"count":24},"Psoriasis",7,{"name":26,"count":27},"Inflammation",5,{"name":29,"count":27},"HIV Infections",{"name":31,"count":27},"Postoperative Pain",{"name":33,"count":34},"Diverticulitis",4,[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05345457","Outpatient Antibiotics Following Previable Rupture of Membranes (pPPROM) Between 18 0\u002F7 and 22 6\u002F7 Weeks Gestational Age","2026-06","Azithromycin Pill",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT03477942","Impact of Mesenchymal Stem Cells in Knee Osteoarthritis","2026-07","Autologous Mesenchymal Stem Cells",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05947760","Magnesium as an Adjuvant Agent for Postoperative Pain","2026-08-31","IV Magnesium Sulfate",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06346262","Seizure Rescue Medication (RM) as Part of a Comprehensive Epilepsy Self-management Package of Care","2026-09-01","Valtoco Nasal Product",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05457972","Postpartum Vaginal Estrogen for Breastfeeding Patients","2026-09-30","Estradiol",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT05270733","Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics","2026-12-31","Ustekinumab",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT07174440","Contrast and Anesthetic Level With Lumbar Erector Spinae Plan (ESP) Block","2027-01-25","Ropivacaine",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT07497737","OMT for Adhesive Capsulitis","2027-04-01","Intra-articular",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT07091123","Patient Preference and Long-term Outcomes in Persistent Spinal Pain Syndrome: A Prospective Study Comparing Spinal Cord Stimulation to Intrathecal Drug Delivery.","2027-08-11","Bupivacain 0.625%\u002FFentanyl 2mcg\u002Fml",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT06997198","Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual\u002FDevelopmental Disabilities","2027-10-01","Deutetrabenazine Oral",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,118,146,164,188,209,232,254,277,312,336,368,392,430,448,466,542,592,646,682,713,748,787,812,835,860,878,902,931,949,976,1005,1023,1048,1073,1091,1117,1142,1160,1184,1208,1235,1253,1278,1301,1326,1352,1370,1388,1415,1441,1463,1485,1508,1534,1561,1579,1597,1621,1648,1673,1691,1717,1742,1760,1784,1811,1836,1861,1884,1909,1935,1961,1985,2009,2027,2050,2073,2097,2120,2144,2166,2191,2209,2227,2252,2275,2303,2321,2339,2357,2383,2410,2436,2461,2479,2497,2520,2544,2583,2637,2680,2706,2728,2746,2764,2782,2800,2824,2847,2865,2889,2907,2934,2961,2979,2997,3015,3040,3058,3081,3099,3117,3142,3166,3184,3202,3220,3242,3264,3287,3309,3335,3353,3371,3389],{"intervention":55,"totalTrials":95,"cells":96},1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":116},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":54},[108],{"nctId":52,"briefTitle":53,"status":109,"phases":110,"primaryCompletion":54,"completion":54,"start":111,"enrollment":112,"conditions":113,"interventions":115},"RECRUITING",[91],"2024-03-05",30,[114],"Epilepsy",[55],{"trials":117,"activeCount":99},[],{"intervention":40,"totalTrials":95,"cells":119},{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":126,"PHASE4":128,"NA":144},{"trials":121,"activeCount":99},[],{"trials":123,"activeCount":99},[],{"trials":125,"activeCount":99},[],{"trials":127,"activeCount":99},[],{"trials":129,"activeCount":95,"soonestReadout":39},[130],{"nctId":37,"briefTitle":38,"status":109,"phases":131,"primaryCompletion":39,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":142},[91],"2027-06","2023-01-13",88,[136,137,138,139,140,141],"Pregnancy Preterm","Pregnancy Prom","PROM, Preterm (Pregnancy)","PROM (Pregnancy)","Premat Rupture Membranes Preterm Unspec to Length of Time Between Rupture\u002FLabor","Premature Birth",[40,143],"Amoxicillin Pill",{"trials":145,"activeCount":99},[],{"intervention":143,"totalTrials":95,"cells":147},{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":162},{"trials":149,"activeCount":99},[],{"trials":151,"activeCount":99},[],{"trials":153,"activeCount":99},[],{"trials":155,"activeCount":99},[],{"trials":157,"activeCount":95,"soonestReadout":39},[158],{"nctId":37,"briefTitle":38,"status":109,"phases":159,"primaryCompletion":39,"completion":132,"start":133,"enrollment":134,"conditions":160,"interventions":161},[91],[136,137,138,139,140,141],[40,143],{"trials":163,"activeCount":99},[],{"intervention":85,"totalTrials":95,"cells":165},{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":170,"PHASE3":172,"PHASE4":174,"NA":186},{"trials":167,"activeCount":99},[],{"trials":169,"activeCount":99},[],{"trials":171,"activeCount":99},[],{"trials":173,"activeCount":99},[],{"trials":175,"activeCount":95,"soonestReadout":84},[176],{"nctId":82,"briefTitle":83,"status":177,"phases":178,"primaryCompletion":84,"completion":84,"start":179,"enrollment":180,"conditions":181,"interventions":185},"NOT_YET_RECRUITING",[91],"2026-05-01",25,[182,183,184],"Tardive Dyskinesia","Intellectual Disability","Developmental Disabilities",[85],{"trials":187,"activeCount":99},[],{"intervention":80,"totalTrials":95,"cells":189},{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":196,"PHASE4":198,"NA":207},{"trials":191,"activeCount":99},[],{"trials":193,"activeCount":99},[],{"trials":195,"activeCount":99},[],{"trials":197,"activeCount":99},[],{"trials":199,"activeCount":95,"soonestReadout":79},[200],{"nctId":77,"briefTitle":78,"status":109,"phases":201,"primaryCompletion":79,"completion":79,"start":202,"enrollment":203,"conditions":204,"interventions":206},[91],"2025-10-13",36,[205],"Persistent Spinal Pain Syndrome",[80],{"trials":208,"activeCount":99},[],{"intervention":75,"totalTrials":95,"cells":210},{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":217,"PHASE4":219,"NA":230},{"trials":212,"activeCount":99},[],{"trials":214,"activeCount":99},[],{"trials":216,"activeCount":99},[],{"trials":218,"activeCount":99},[],{"trials":220,"activeCount":95,"soonestReadout":74},[221],{"nctId":72,"briefTitle":73,"status":177,"phases":222,"primaryCompletion":74,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":229},[91],"2028-05-01","2026-04-01",300,[227,228],"Adhesive Capsulitis of the Shoulder","Frozen Shoulder",[75],{"trials":231,"activeCount":99},[],{"intervention":50,"totalTrials":95,"cells":233},{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":238,"PHASE3":240,"PHASE4":242,"NA":252},{"trials":235,"activeCount":99},[],{"trials":237,"activeCount":99},[],{"trials":239,"activeCount":99},[],{"trials":241,"activeCount":99},[],{"trials":243,"activeCount":95,"soonestReadout":49},[244],{"nctId":47,"briefTitle":48,"status":245,"phases":246,"primaryCompletion":49,"completion":49,"start":247,"enrollment":248,"conditions":249,"interventions":251},"ACTIVE_NOT_RECRUITING",[91],"2025-03-10",50,[250],"Pain, Postoperative",[50],{"trials":253,"activeCount":99},[],{"intervention":60,"totalTrials":95,"cells":255},{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":264,"NA":275},{"trials":257,"activeCount":99},[],{"trials":259,"activeCount":99},[],{"trials":261,"activeCount":99},[],{"trials":263,"activeCount":99},[],{"trials":265,"activeCount":95,"soonestReadout":59},[266],{"nctId":57,"briefTitle":58,"status":109,"phases":267,"primaryCompletion":59,"completion":59,"start":268,"enrollment":269,"conditions":270,"interventions":274},[91],"2025-02-22",100,[271,272,273],"Breastfeeding","Postpartum Sexual Dysfunction","Vaginal Atrophy",[60],{"trials":276,"activeCount":99},[],{"intervention":65,"totalTrials":278,"cells":279},2,{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":286,"PHASE4":288,"NA":296},{"trials":281,"activeCount":99},[],{"trials":283,"activeCount":99},[],{"trials":285,"activeCount":99},[],{"trials":287,"activeCount":99},[],{"trials":289,"activeCount":95,"soonestReadout":64},[290],{"nctId":62,"briefTitle":63,"status":109,"phases":291,"primaryCompletion":64,"completion":64,"start":292,"enrollment":293,"conditions":294,"interventions":295},[91],"2022-11-10",56,[23],[65],{"trials":297,"activeCount":99},[298],{"nctId":299,"briefTitle":300,"status":301,"phases":302,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":307},"NCT02330380","Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation","COMPLETED",[],"2016-12","2013-04",26,[23,26],[308,65,309,310,311],"Methotrexate","Etanercept","Adalimumab","Acitretin",{"intervention":313,"totalTrials":95,"cells":314},"Milk thistle",{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":330,"PHASE4":332,"NA":334},{"trials":316,"activeCount":99},[],{"trials":318,"activeCount":99},[],{"trials":320,"activeCount":95,"soonestReadout":325},[321],{"nctId":322,"briefTitle":323,"status":109,"phases":324,"primaryCompletion":325,"completion":325,"start":326,"enrollment":16,"conditions":327,"interventions":329},"NCT06477146","Milk Thistle Clinical Trial in Pediatric NAFLD",[89],"2029-01-31","2024-12-19",[328],"Non-Alcoholic Fatty Liver Disease (NAFLD)",[313],{"trials":331,"activeCount":99},[],{"trials":333,"activeCount":99},[],{"trials":335,"activeCount":99},[],{"intervention":337,"totalTrials":278,"cells":338},"Memantine",{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":351,"PHASE3":362,"PHASE4":364,"NA":366},{"trials":340,"activeCount":99},[],{"trials":342,"activeCount":95,"soonestReadout":347},[343],{"nctId":344,"briefTitle":345,"status":177,"phases":346,"primaryCompletion":347,"completion":347,"start":39,"enrollment":180,"conditions":348,"interventions":350},"NCT07531940","Escalating Doses of Memantine in Down Syndrome (MEDS-123)",[88],"2028-05",[349,183],"Down Syndrome",[337],{"trials":352,"activeCount":99},[353],{"nctId":354,"briefTitle":355,"status":301,"phases":356,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":361},"NCT02304302","Down Syndrome Memantine Follow-up Study",[89],"2020-07-22","2014-10",160,[349,183],[337],{"trials":363,"activeCount":99},[],{"trials":365,"activeCount":99},[],{"trials":367,"activeCount":99},[],{"intervention":45,"totalTrials":95,"cells":369},{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":384,"PHASE3":386,"PHASE4":388,"NA":390},{"trials":371,"activeCount":99},[],{"trials":373,"activeCount":95,"soonestReadout":44},[374],{"nctId":42,"briefTitle":43,"status":245,"phases":375,"primaryCompletion":44,"completion":44,"start":376,"enrollment":377,"conditions":378,"interventions":383},[88],"2018-10-01",16,[379,380,381,382],"Musculoskeletal Pain","Knee Osteoarthritis","Cartilage Injury","Cartilage Degeneration",[45],{"trials":385,"activeCount":99},[],{"trials":387,"activeCount":99},[],{"trials":389,"activeCount":99},[],{"trials":391,"activeCount":99},[],{"intervention":393,"totalTrials":278,"cells":394},"Dexmedetomidine",{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":416,"PHASE4":418,"NA":420},{"trials":396,"activeCount":99},[],{"trials":398,"activeCount":99},[],{"trials":400,"activeCount":99},[401],{"nctId":402,"briefTitle":403,"status":404,"phases":405,"primaryCompletion":406,"completion":406,"start":407,"enrollment":24,"conditions":408,"interventions":413},"NCT01845441","Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions","TERMINATED",[89],"2021-12","2012-04",[409,410,411,412],"Stroke","Brain Ischemia","Vasospasm, Intracranial","Hemorrhage, Intracranial",[393,414,415],"Fentanyl","Midazolam",{"trials":417,"activeCount":99},[],{"trials":419,"activeCount":99},[],{"trials":421,"activeCount":95,"soonestReadout":69},[422],{"nctId":67,"briefTitle":68,"status":109,"phases":423,"primaryCompletion":69,"completion":69,"start":424,"enrollment":425,"conditions":426,"interventions":428},[92],"2025-09-15",32,[427],"Pain",[70,393,429],"Iohexol",{"intervention":70,"totalTrials":95,"cells":431},{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":438,"PHASE4":440,"NA":442},{"trials":433,"activeCount":99},[],{"trials":435,"activeCount":99},[],{"trials":437,"activeCount":99},[],{"trials":439,"activeCount":99},[],{"trials":441,"activeCount":99},[],{"trials":443,"activeCount":95,"soonestReadout":69},[444],{"nctId":67,"briefTitle":68,"status":109,"phases":445,"primaryCompletion":69,"completion":69,"start":424,"enrollment":425,"conditions":446,"interventions":447},[92],[427],[70,393,429],{"intervention":429,"totalTrials":95,"cells":449},{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":456,"PHASE4":458,"NA":460},{"trials":451,"activeCount":99},[],{"trials":453,"activeCount":99},[],{"trials":455,"activeCount":99},[],{"trials":457,"activeCount":99},[],{"trials":459,"activeCount":99},[],{"trials":461,"activeCount":95,"soonestReadout":69},[462],{"nctId":67,"briefTitle":68,"status":109,"phases":463,"primaryCompletion":69,"completion":69,"start":424,"enrollment":425,"conditions":464,"interventions":465},[92],[427],[70,393,429],{"intervention":467,"totalTrials":27,"cells":468},"Ketorolac",{"EARLY_PHASE1":469,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":524,"NA":540},{"trials":470,"activeCount":99},[471],{"nctId":472,"briefTitle":473,"status":301,"phases":474,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":480},"NCT03393364","Pain Management in Outpatient Urologic Procedures",[87],"2020-06-01","2018-04-01",150,[479],"Urologic Diseases",[481,467],"Oxycodone",{"trials":483,"activeCount":99},[],{"trials":485,"activeCount":99},[],{"trials":487,"activeCount":99},[488,499,511],{"nctId":489,"briefTitle":490,"status":301,"phases":491,"primaryCompletion":492,"completion":493,"start":494,"enrollment":495,"conditions":496,"interventions":498},"NCT03967847","Oral Ketorolac for Arthroscopic Rotator Cuff Repair",[90],"2020-10-14","2021-05-17","2019-02-11",44,[497,31],"Rotator Cuff Tear",[467],{"nctId":500,"briefTitle":501,"status":301,"phases":502,"primaryCompletion":503,"completion":504,"start":505,"enrollment":506,"conditions":507,"interventions":509},"NCT04246554","Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic ACL Surgery",[90],"2020-10-09","2021-01-01","2019-05-21",49,[508,31],"ACL Injury",[467,510],"Oxycodone-Acetaminophen",{"nctId":512,"briefTitle":513,"status":301,"phases":514,"primaryCompletion":515,"completion":515,"start":516,"enrollment":517,"conditions":518,"interventions":523},"NCT04246541","Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic Meniscus Surgery",[90],"2021-09-12","2019-04-23",48,[519,250,520,521,522],"Meniscus Tear, Tibial","Postoperative Complications","Ketorolac Adverse Reaction","Opioid Use",[467,510],{"trials":525,"activeCount":99},[526],{"nctId":527,"briefTitle":528,"status":301,"phases":529,"primaryCompletion":530,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":539},"NCT02509312","Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery",[91],"2017-10","2016-05",70,[534,535,522,536,537,31,521,538],"Analgesia, Obstetrical","Postpartum Hemorrhage","Nonsteroidals (NSAIDs)Toxicity","Coagulation Defect; Postpartum","Blood Loss, Postoperative",[467],{"trials":541,"activeCount":99},[],{"intervention":543,"totalTrials":34,"cells":544},"Aripiprazole",{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":551,"PHASE4":571,"NA":590},{"trials":546,"activeCount":99},[],{"trials":548,"activeCount":99},[],{"trials":550,"activeCount":99},[],{"trials":552,"activeCount":99},[553,563],{"nctId":554,"briefTitle":555,"status":301,"phases":556,"primaryCompletion":557,"completion":558,"start":559,"enrollment":560,"conditions":561,"interventions":562},"NCT00194012","Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder",[90],"2012-05","2012-06","2004-08",62,[15],[543],{"nctId":564,"briefTitle":565,"status":301,"phases":566,"primaryCompletion":567,"completion":567,"start":559,"enrollment":568,"conditions":569,"interventions":570},"NCT00194077","Study of Aripiprazole (Abilify) in Children With Symptoms of Mania",[90],"2011-01",60,[15],[543],{"trials":572,"activeCount":99},[573,582],{"nctId":574,"briefTitle":575,"status":301,"phases":576,"primaryCompletion":577,"completion":577,"start":578,"enrollment":9,"conditions":579,"interventions":581},"NCT00221962","Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)",[91],"2007-04","2005-04",[580],"Attention Deficit Hyperactivity Disorder",[543],{"nctId":583,"briefTitle":584,"status":301,"phases":585,"primaryCompletion":586,"completion":586,"start":587,"enrollment":16,"conditions":588,"interventions":589},"NCT00194038","Aripiprazole in Late Life Bipolar Disorder",[91],"2006-06","2004-04",[15],[543],{"trials":591,"activeCount":99},[],{"intervention":593,"totalTrials":34,"cells":594},"Lithium",{"EARLY_PHASE1":595,"PHASE1":597,"PHASE2":599,"PHASE3":601,"PHASE4":632,"NA":644},{"trials":596,"activeCount":99},[],{"trials":598,"activeCount":99},[],{"trials":600,"activeCount":99},[],{"trials":602,"activeCount":99},[603,613,622],{"nctId":604,"briefTitle":605,"status":404,"phases":606,"primaryCompletion":607,"completion":607,"start":608,"enrollment":506,"conditions":609,"interventions":610},"NCT00063362","Combination Therapy for the Treatment of Bipolar Disorders",[90],"2007-07","2002-02",[15],[593,611,612],"Lamotrigine","Divalproex",{"nctId":614,"briefTitle":615,"status":301,"phases":616,"primaryCompletion":617,"completion":617,"start":618,"enrollment":619,"conditions":620,"interventions":621},"NCT00194129","Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder",[90],"2006-09","1997-11",31,[15],[593,612],{"nctId":623,"briefTitle":624,"status":301,"phases":625,"primaryCompletion":626,"completion":627,"start":628,"enrollment":629,"conditions":630,"interventions":631},"NCT00221975","Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling",[90],"2007-06","2007-12","2002-07",98,[15],[612,611,593],{"trials":633,"activeCount":99},[634],{"nctId":635,"briefTitle":636,"status":404,"phases":637,"primaryCompletion":638,"completion":638,"start":639,"enrollment":640,"conditions":641,"interventions":642},"NCT01526148","Gao Bipolar Spectrum Lithium\u002FQuetiapine Study",[91],"2015-01","2012-01",42,[15],[593,643],"Quetiapine",{"trials":645,"activeCount":99},[],{"intervention":647,"totalTrials":278,"cells":648},"Spironolactone",{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":653,"PHASE3":655,"PHASE4":657,"NA":680},{"trials":650,"activeCount":99},[],{"trials":652,"activeCount":99},[],{"trials":654,"activeCount":99},[],{"trials":656,"activeCount":99},[],{"trials":658,"activeCount":99},[659,669],{"nctId":660,"briefTitle":661,"status":301,"phases":662,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":666,"interventions":668},"NCT02169089","Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial",[91],"2022-04-29","2016-01",79,[667],"Atherosclerosis",[647],{"nctId":670,"briefTitle":671,"status":404,"phases":672,"primaryCompletion":673,"completion":674,"start":675,"enrollment":19,"conditions":676,"interventions":679},"NCT03597035","Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On",[91],"2020-07-23","2020-07-31","2018-07-17",[677,678],"Type2 Diabetes","Hyperkalemia",[647],{"trials":681,"activeCount":99},[],{"intervention":414,"totalTrials":278,"cells":683},{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":694,"PHASE4":696,"NA":711},{"trials":685,"activeCount":99},[],{"trials":687,"activeCount":99},[],{"trials":689,"activeCount":99},[690],{"nctId":402,"briefTitle":403,"status":404,"phases":691,"primaryCompletion":406,"completion":406,"start":407,"enrollment":24,"conditions":692,"interventions":693},[89],[409,410,411,412],[393,414,415],{"trials":695,"activeCount":99},[],{"trials":697,"activeCount":99},[698],{"nctId":699,"briefTitle":700,"status":301,"phases":701,"primaryCompletion":702,"completion":702,"start":703,"enrollment":203,"conditions":704,"interventions":709},"NCT03523000","Determining the Prognostic Value of Continuous Intrathecal Infusion",[91],"2021-10-12","2017-10-18",[705,706,707,708],"Lumbar Post-Laminectomy Syndrome","Chronic Low Back Pain","Vertebral Compression Fracture","Failed Back Surgery Syndrome",[710,414],"Bupivacaine",{"trials":712,"activeCount":99},[],{"intervention":714,"totalTrials":278,"cells":715},"celecoxib",{"EARLY_PHASE1":716,"PHASE1":718,"PHASE2":720,"PHASE3":733,"PHASE4":735,"NA":746},{"trials":717,"activeCount":99},[],{"trials":719,"activeCount":99},[],{"trials":721,"activeCount":99},[722],{"nctId":723,"briefTitle":724,"status":725,"phases":726,"primaryCompletion":727,"completion":728,"start":729,"enrollment":112,"conditions":730,"interventions":732},"NCT00597415","Efficacy of Celecoxib 200mg in Relieving Pain and Walking Dysfunction in Osteoarthritis of the Knee","UNKNOWN",[89],"2008-02","2008-03","2004-12",[731],"Osteoarthritis of the Knee",[714],{"trials":734,"activeCount":99},[],{"trials":736,"activeCount":99},[737],{"nctId":738,"briefTitle":739,"status":301,"phases":740,"primaryCompletion":741,"completion":741,"start":742,"enrollment":743,"conditions":744,"interventions":745},"NCT00194090","Efficacy of Celecoxib vs Placebo to Prevent Pain in a Paced Walk",[91],"2005-09-01","2004-06",40,[380],[714],{"trials":747,"activeCount":99},[],{"intervention":749,"totalTrials":278,"cells":750},"Clopidogrel",{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":757,"PHASE4":772,"NA":785},{"trials":752,"activeCount":99},[],{"trials":754,"activeCount":99},[],{"trials":756,"activeCount":99},[],{"trials":758,"activeCount":99},[759],{"nctId":760,"briefTitle":761,"status":762,"phases":763,"primaryCompletion":764,"completion":765,"start":766,"enrollment":99,"conditions":767,"interventions":770},"NCT02433587","Short vs Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization","WITHDRAWN",[90],"2021-07","2023-07","2019-10",[768,769],"Peripheral Arterial Disease","Endovascular Procedures",[771,749],"Aspirin",{"trials":773,"activeCount":99},[774],{"nctId":775,"briefTitle":776,"status":301,"phases":777,"primaryCompletion":778,"completion":778,"start":779,"enrollment":568,"conditions":780,"interventions":783},"NCT02486367","Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)",[91],"2019-01","2015-06",[781,26,782],"Aortic Stenosis","Thrombosis",[749,784],"Ticagrelor",{"trials":786,"activeCount":99},[],{"intervention":788,"totalTrials":95,"cells":789},"saproterin dihydrochloride",{"EARLY_PHASE1":790,"PHASE1":792,"PHASE2":794,"PHASE3":796,"PHASE4":798,"NA":810},{"trials":791,"activeCount":99},[],{"trials":793,"activeCount":99},[],{"trials":795,"activeCount":99},[],{"trials":797,"activeCount":99},[],{"trials":799,"activeCount":99},[800],{"nctId":801,"briefTitle":802,"status":301,"phases":803,"primaryCompletion":804,"completion":805,"start":806,"enrollment":24,"conditions":807,"interventions":809},"NCT02677870","The Effectiveness of Kuvan in Amish PKU Patients",[91],"2018-11-20","2019-01-01","2018-01-22",[808],"Phenylketonuria",[788],{"trials":811,"activeCount":99},[],{"intervention":813,"totalTrials":95,"cells":814},"ziprasidone",{"EARLY_PHASE1":815,"PHASE1":817,"PHASE2":819,"PHASE3":821,"PHASE4":823,"NA":833},{"trials":816,"activeCount":99},[],{"trials":818,"activeCount":99},[],{"trials":820,"activeCount":99},[],{"trials":822,"activeCount":99},[],{"trials":824,"activeCount":99},[825],{"nctId":826,"briefTitle":827,"status":301,"phases":828,"primaryCompletion":829,"completion":829,"start":567,"enrollment":112,"conditions":830,"interventions":832},"NCT01293825","Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad)",[91],"2012-08",[831,15],"Medication Adherence",[813],{"trials":834,"activeCount":99},[],{"intervention":836,"totalTrials":95,"cells":837},"Fluticasone Propionate",{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":844,"PHASE4":846,"NA":858},{"trials":839,"activeCount":99},[],{"trials":841,"activeCount":99},[],{"trials":843,"activeCount":99},[],{"trials":845,"activeCount":99},[],{"trials":847,"activeCount":99},[848],{"nctId":849,"briefTitle":850,"status":301,"phases":851,"primaryCompletion":852,"completion":852,"start":853,"enrollment":9,"conditions":854,"interventions":856},"NCT05444543","Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis)",[91],"2023-10-13","2021-11-17",[855],"Eosinophilic Esophagitis",[836,857],"Budesonide",{"trials":859,"activeCount":99},[],{"intervention":857,"totalTrials":95,"cells":861},{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":868,"PHASE4":870,"NA":876},{"trials":863,"activeCount":99},[],{"trials":865,"activeCount":99},[],{"trials":867,"activeCount":99},[],{"trials":869,"activeCount":99},[],{"trials":871,"activeCount":99},[872],{"nctId":849,"briefTitle":850,"status":301,"phases":873,"primaryCompletion":852,"completion":852,"start":853,"enrollment":9,"conditions":874,"interventions":875},[91],[855],[836,857],{"trials":877,"activeCount":99},[],{"intervention":879,"totalTrials":95,"cells":880},"Valproate",{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":885,"PHASE3":887,"PHASE4":889,"NA":900},{"trials":882,"activeCount":99},[],{"trials":884,"activeCount":99},[],{"trials":886,"activeCount":99},[],{"trials":888,"activeCount":99},[],{"trials":890,"activeCount":99},[891],{"nctId":892,"briefTitle":893,"status":301,"phases":894,"primaryCompletion":895,"completion":895,"start":896,"enrollment":16,"conditions":897,"interventions":899},"NCT00194025","Valproate in Late Life Schizophrenia",[91],"2006-11","2004-11",[898],"Schizophrenia",[879],{"trials":901,"activeCount":99},[],{"intervention":903,"totalTrials":95,"cells":904},"Premarin",{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":911,"PHASE4":913,"NA":929},{"trials":906,"activeCount":99},[],{"trials":908,"activeCount":99},[],{"trials":910,"activeCount":99},[],{"trials":912,"activeCount":99},[],{"trials":914,"activeCount":99},[915],{"nctId":916,"briefTitle":917,"status":762,"phases":918,"primaryCompletion":919,"completion":920,"start":921,"enrollment":99,"conditions":922,"interventions":927},"NCT02860897","Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery",[91],"2017-04","2017-07","2016-07",[923,924,925,926],"Estrogen","Menopause","Pelvic Floor Disorders","Surgery",[903,928],"Vagifem",{"trials":930,"activeCount":99},[],{"intervention":928,"totalTrials":95,"cells":932},{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":937,"PHASE3":939,"PHASE4":941,"NA":947},{"trials":934,"activeCount":99},[],{"trials":936,"activeCount":99},[],{"trials":938,"activeCount":99},[],{"trials":940,"activeCount":99},[],{"trials":942,"activeCount":99},[943],{"nctId":916,"briefTitle":917,"status":762,"phases":944,"primaryCompletion":919,"completion":920,"start":921,"enrollment":99,"conditions":945,"interventions":946},[91],[923,924,925,926],[903,928],{"trials":948,"activeCount":99},[],{"intervention":950,"totalTrials":95,"cells":951},"Graded Oral Amoxicillin Challenge",{"EARLY_PHASE1":952,"PHASE1":954,"PHASE2":956,"PHASE3":958,"PHASE4":960,"NA":974},{"trials":953,"activeCount":99},[],{"trials":955,"activeCount":99},[],{"trials":957,"activeCount":99},[],{"trials":959,"activeCount":99},[],{"trials":961,"activeCount":99},[962],{"nctId":963,"briefTitle":964,"status":301,"phases":965,"primaryCompletion":966,"completion":966,"start":967,"enrollment":743,"conditions":968,"interventions":973},"NCT05020327","Inpatient Penicillin Allergy Delabeling Study",[91],"2022-03-30","2021-09-22",[969,970,971,972],"Penicillin Allergy","Penicillin Sensitivity","Penicillin Reaction","Penicillin Intolerance",[950],{"trials":975,"activeCount":99},[],{"intervention":977,"totalTrials":95,"cells":978},"Injectable 1 ml\u002Fkg of 0.25% ropivacaine with 1mcg\u002Fkg dexmedetomidine",{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":983,"PHASE3":985,"PHASE4":987,"NA":1003},{"trials":980,"activeCount":99},[],{"trials":982,"activeCount":99},[],{"trials":984,"activeCount":99},[],{"trials":986,"activeCount":99},[],{"trials":988,"activeCount":99},[989],{"nctId":990,"briefTitle":991,"status":762,"phases":992,"primaryCompletion":993,"completion":994,"start":995,"enrollment":99,"conditions":996,"interventions":1001},"NCT05708989","Caudal vs. Pudendal Block in Peds GU",[91],"2025-02","2025-05","2023-03-06",[997,998,999,1000],"Hypospadias","Penile Torsion","Chordee","Phimosis",[977,1002],"Injection of 0.5 ml\u002Fkg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg\u002Fkg dexmetomedine.",{"trials":1004,"activeCount":99},[],{"intervention":1002,"totalTrials":95,"cells":1006},{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1013,"PHASE4":1015,"NA":1021},{"trials":1008,"activeCount":99},[],{"trials":1010,"activeCount":99},[],{"trials":1012,"activeCount":99},[],{"trials":1014,"activeCount":99},[],{"trials":1016,"activeCount":99},[1017],{"nctId":990,"briefTitle":991,"status":762,"phases":1018,"primaryCompletion":993,"completion":994,"start":995,"enrollment":99,"conditions":1019,"interventions":1020},[91],[997,998,999,1000],[977,1002],{"trials":1022,"activeCount":99},[],{"intervention":1024,"totalTrials":95,"cells":1025},"MedJet Device with intralesional triamcinolone",{"EARLY_PHASE1":1026,"PHASE1":1028,"PHASE2":1030,"PHASE3":1032,"PHASE4":1034,"NA":1046},{"trials":1027,"activeCount":99},[],{"trials":1029,"activeCount":99},[],{"trials":1031,"activeCount":99},[],{"trials":1033,"activeCount":99},[],{"trials":1035,"activeCount":99},[1036],{"nctId":1037,"briefTitle":1038,"status":404,"phases":1039,"primaryCompletion":1040,"completion":1040,"start":1041,"enrollment":1042,"conditions":1043,"interventions":1045},"NCT05278858","Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata",[91],"2023-06-06","2022-03-24",3,[1044],"Alopecia Areata",[1024],{"trials":1047,"activeCount":99},[],{"intervention":1049,"totalTrials":95,"cells":1050},"Non-buffered Anesthetic",{"EARLY_PHASE1":1051,"PHASE1":1053,"PHASE2":1055,"PHASE3":1057,"PHASE4":1059,"NA":1071},{"trials":1052,"activeCount":99},[],{"trials":1054,"activeCount":99},[],{"trials":1056,"activeCount":99},[],{"trials":1058,"activeCount":99},[],{"trials":1060,"activeCount":99},[1061],{"nctId":1062,"briefTitle":1063,"status":301,"phases":1064,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":16,"conditions":1067,"interventions":1069},"NCT05757648","Buffered Local Anesthetic",[91],"2023-06-12","2020-12-08",[1068],"Dental Pain",[1049,1070],"Buffered Anesthetic",{"trials":1072,"activeCount":99},[],{"intervention":1070,"totalTrials":95,"cells":1074},{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1079,"PHASE3":1081,"PHASE4":1083,"NA":1089},{"trials":1076,"activeCount":99},[],{"trials":1078,"activeCount":99},[],{"trials":1080,"activeCount":99},[],{"trials":1082,"activeCount":99},[],{"trials":1084,"activeCount":99},[1085],{"nctId":1062,"briefTitle":1063,"status":301,"phases":1086,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":16,"conditions":1087,"interventions":1088},[91],[1068],[1049,1070],{"trials":1090,"activeCount":99},[],{"intervention":1092,"totalTrials":95,"cells":1093},"Ertugliflozin 5 mg",{"EARLY_PHASE1":1094,"PHASE1":1096,"PHASE2":1098,"PHASE3":1100,"PHASE4":1102,"NA":1115},{"trials":1095,"activeCount":99},[],{"trials":1097,"activeCount":99},[],{"trials":1099,"activeCount":99},[],{"trials":1101,"activeCount":99},[],{"trials":1103,"activeCount":99},[1104],{"nctId":1105,"briefTitle":1106,"status":404,"phases":1107,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":1110,"conditions":1111,"interventions":1114},"NCT04071626","Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure",[91],"2023-01-11","2020-03-01",9,[1112,1113],"Heart Failure, Diastolic","Diabetes Mellitus, Type 2",[1092],{"trials":1116,"activeCount":99},[],{"intervention":1118,"totalTrials":95,"cells":1119},"Dysport",{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1126,"PHASE4":1128,"NA":1140},{"trials":1121,"activeCount":99},[],{"trials":1123,"activeCount":99},[],{"trials":1125,"activeCount":99},[],{"trials":1127,"activeCount":99},[],{"trials":1129,"activeCount":99},[1130],{"nctId":1131,"briefTitle":1132,"status":404,"phases":1133,"primaryCompletion":1134,"completion":1134,"start":1135,"enrollment":1110,"conditions":1136,"interventions":1138},"NCT01459666","Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer",[91],"2019-08","2011-09",[1137],"Scar",[1118,1139],"Bacteriostatic 0.9% Sodium Chloride",{"trials":1141,"activeCount":99},[],{"intervention":1139,"totalTrials":95,"cells":1143},{"EARLY_PHASE1":1144,"PHASE1":1146,"PHASE2":1148,"PHASE3":1150,"PHASE4":1152,"NA":1158},{"trials":1145,"activeCount":99},[],{"trials":1147,"activeCount":99},[],{"trials":1149,"activeCount":99},[],{"trials":1151,"activeCount":99},[],{"trials":1153,"activeCount":99},[1154],{"nctId":1131,"briefTitle":1132,"status":404,"phases":1155,"primaryCompletion":1134,"completion":1134,"start":1135,"enrollment":1110,"conditions":1156,"interventions":1157},[91],[1137],[1118,1139],{"trials":1159,"activeCount":99},[],{"intervention":1161,"totalTrials":95,"cells":1162},"Risedronate",{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1167,"PHASE3":1169,"PHASE4":1171,"NA":1182},{"trials":1164,"activeCount":99},[],{"trials":1166,"activeCount":99},[],{"trials":1168,"activeCount":99},[],{"trials":1170,"activeCount":99},[],{"trials":1172,"activeCount":99},[1173],{"nctId":1174,"briefTitle":1175,"status":762,"phases":1176,"primaryCompletion":1177,"completion":567,"start":1178,"enrollment":99,"conditions":1179,"interventions":1181},"NCT00594334","Effect of Actonel on Periodontal Health of Postmenopausal Women",[91],"2010-01","2008-01",[1180],"Periodontal Disease",[1161],{"trials":1183,"activeCount":99},[],{"intervention":1185,"totalTrials":95,"cells":1186},"Leukocyte rich platelet rich plasma",{"EARLY_PHASE1":1187,"PHASE1":1189,"PHASE2":1191,"PHASE3":1193,"PHASE4":1195,"NA":1206},{"trials":1188,"activeCount":99},[],{"trials":1190,"activeCount":99},[],{"trials":1192,"activeCount":99},[],{"trials":1194,"activeCount":99},[],{"trials":1196,"activeCount":99},[1197],{"nctId":1198,"briefTitle":1199,"status":762,"phases":1200,"primaryCompletion":1201,"completion":1201,"start":1202,"enrollment":99,"conditions":1203,"interventions":1205},"NCT04384809","Platelet Rich Plasma Injection vs Percutaneous Tenotomy for Common Extensor Tendinopathy",[91],"2023-05-01","2023-01-01",[1204],"Lateral Epicondylitis (Tennis Elbow)",[1185],{"trials":1207,"activeCount":99},[],{"intervention":1209,"totalTrials":95,"cells":1210},"Ice T",{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1215,"PHASE3":1217,"PHASE4":1219,"NA":1233},{"trials":1212,"activeCount":99},[],{"trials":1214,"activeCount":99},[],{"trials":1216,"activeCount":99},[],{"trials":1218,"activeCount":99},[],{"trials":1220,"activeCount":99},[1221],{"nctId":1222,"briefTitle":1223,"status":301,"phases":1224,"primaryCompletion":1225,"completion":1226,"start":1227,"enrollment":1228,"conditions":1229,"interventions":1231},"NCT03052816","Ice T Postoperative Multimodal Pain Regimen in FPMRS Surgery",[91],"2018-06-01","2018-06-30","2017-04-01",66,[250,1230],"Pelvic Organ Prolapse",[1209,1232],"Motrin\u002FPercocet\u002FDilaudid for breakthrough",{"trials":1234,"activeCount":99},[],{"intervention":1232,"totalTrials":95,"cells":1236},{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1241,"PHASE3":1243,"PHASE4":1245,"NA":1251},{"trials":1238,"activeCount":99},[],{"trials":1240,"activeCount":99},[],{"trials":1242,"activeCount":99},[],{"trials":1244,"activeCount":99},[],{"trials":1246,"activeCount":99},[1247],{"nctId":1222,"briefTitle":1223,"status":301,"phases":1248,"primaryCompletion":1225,"completion":1226,"start":1227,"enrollment":1228,"conditions":1249,"interventions":1250},[91],[250,1230],[1209,1232],{"trials":1252,"activeCount":99},[],{"intervention":1254,"totalTrials":95,"cells":1255},"Intravesical Botox",{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1262,"PHASE4":1264,"NA":1276},{"trials":1257,"activeCount":99},[],{"trials":1259,"activeCount":99},[],{"trials":1261,"activeCount":99},[],{"trials":1263,"activeCount":99},[],{"trials":1265,"activeCount":99},[1266],{"nctId":1267,"briefTitle":1268,"status":762,"phases":1269,"primaryCompletion":1270,"completion":1270,"start":1271,"enrollment":99,"conditions":1272,"interventions":1275},"NCT05393921","The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder",[91],"2027-07","2026-06-01",[1273,1274],"Benign Prostatic Hyperplasia","Overactive Bladder",[1254],{"trials":1277,"activeCount":99},[],{"intervention":1279,"totalTrials":95,"cells":1280},"Asenapine",{"EARLY_PHASE1":1281,"PHASE1":1283,"PHASE2":1285,"PHASE3":1287,"PHASE4":1289,"NA":1299},{"trials":1282,"activeCount":99},[],{"trials":1284,"activeCount":99},[],{"trials":1286,"activeCount":99},[],{"trials":1288,"activeCount":99},[],{"trials":1290,"activeCount":99},[1291],{"nctId":1292,"briefTitle":1293,"status":301,"phases":1294,"primaryCompletion":1295,"completion":1295,"start":1296,"enrollment":11,"conditions":1297,"interventions":1298},"NCT01460290","Asenapine in the Treatment of Older Adults With Bipolar Disorder",[91],"2014-03","2011-10",[15],[1279],{"trials":1300,"activeCount":99},[],{"intervention":1302,"totalTrials":95,"cells":1303},"ketamine",{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1310,"PHASE4":1312,"NA":1324},{"trials":1305,"activeCount":99},[],{"trials":1307,"activeCount":99},[],{"trials":1309,"activeCount":99},[],{"trials":1311,"activeCount":99},[],{"trials":1313,"activeCount":99},[1314],{"nctId":1315,"briefTitle":1316,"status":762,"phases":1317,"primaryCompletion":1318,"completion":1318,"start":1319,"enrollment":99,"conditions":1320,"interventions":1323},"NCT07182032","Ketamine in Central Sensitization",[91],"2028-06-30","2026-02-01",[1321,1322],"Endometriosis","Chronic Pelvic Pain",[1302],{"trials":1325,"activeCount":99},[],{"intervention":1327,"totalTrials":95,"cells":1328},"Opioid",{"EARLY_PHASE1":1329,"PHASE1":1331,"PHASE2":1333,"PHASE3":1335,"PHASE4":1337,"NA":1350},{"trials":1330,"activeCount":99},[],{"trials":1332,"activeCount":99},[],{"trials":1334,"activeCount":99},[],{"trials":1336,"activeCount":99},[],{"trials":1338,"activeCount":99},[1339],{"nctId":1340,"briefTitle":1341,"status":301,"phases":1342,"primaryCompletion":1343,"completion":1343,"start":531,"enrollment":1344,"conditions":1345,"interventions":1349},"NCT02886286","Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain",[91],"2017-12",17,[1346,1347,1348],"Pain, Intractable","Breakthrough Pain","Chronic Pain",[710,1327],{"trials":1351,"activeCount":99},[],{"intervention":643,"totalTrials":95,"cells":1353},{"EARLY_PHASE1":1354,"PHASE1":1356,"PHASE2":1358,"PHASE3":1360,"PHASE4":1362,"NA":1368},{"trials":1355,"activeCount":99},[],{"trials":1357,"activeCount":99},[],{"trials":1359,"activeCount":99},[],{"trials":1361,"activeCount":99},[],{"trials":1363,"activeCount":99},[1364],{"nctId":635,"briefTitle":636,"status":404,"phases":1365,"primaryCompletion":638,"completion":638,"start":639,"enrollment":640,"conditions":1366,"interventions":1367},[91],[15],[593,643],{"trials":1369,"activeCount":99},[],{"intervention":784,"totalTrials":95,"cells":1371},{"EARLY_PHASE1":1372,"PHASE1":1374,"PHASE2":1376,"PHASE3":1378,"PHASE4":1380,"NA":1386},{"trials":1373,"activeCount":99},[],{"trials":1375,"activeCount":99},[],{"trials":1377,"activeCount":99},[],{"trials":1379,"activeCount":99},[],{"trials":1381,"activeCount":99},[1382],{"nctId":775,"briefTitle":776,"status":301,"phases":1383,"primaryCompletion":778,"completion":778,"start":779,"enrollment":568,"conditions":1384,"interventions":1385},[91],[781,26,782],[749,784],{"trials":1387,"activeCount":99},[],{"intervention":1389,"totalTrials":95,"cells":1390},"Polyethylene Glycol 3350",{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1395,"PHASE3":1397,"PHASE4":1399,"NA":1413},{"trials":1392,"activeCount":99},[],{"trials":1394,"activeCount":99},[],{"trials":1396,"activeCount":99},[],{"trials":1398,"activeCount":99},[],{"trials":1400,"activeCount":99},[1401],{"nctId":1402,"briefTitle":1403,"status":301,"phases":1404,"primaryCompletion":1405,"completion":1405,"start":1406,"enrollment":1407,"conditions":1408,"interventions":1412},"NCT06159777","Pre-operative Polyethylene Glycol 3350 for Minimally Invasive Urogynecologic Surgery",[91],"2026-03-13","2024-06-05",74,[1409,1410,1411],"Constipation","Surgical Procedure, Unspecified","Prolapse; Female",[1389],{"trials":1414,"activeCount":99},[],{"intervention":612,"totalTrials":1042,"cells":1416},{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1421,"PHASE3":1423,"PHASE4":1437,"NA":1439},{"trials":1418,"activeCount":99},[],{"trials":1420,"activeCount":99},[],{"trials":1422,"activeCount":99},[],{"trials":1424,"activeCount":99},[1425,1429,1433],{"nctId":604,"briefTitle":605,"status":404,"phases":1426,"primaryCompletion":607,"completion":607,"start":608,"enrollment":506,"conditions":1427,"interventions":1428},[90],[15],[593,611,612],{"nctId":614,"briefTitle":615,"status":301,"phases":1430,"primaryCompletion":617,"completion":617,"start":618,"enrollment":619,"conditions":1431,"interventions":1432},[90],[15],[593,612],{"nctId":623,"briefTitle":624,"status":301,"phases":1434,"primaryCompletion":626,"completion":627,"start":628,"enrollment":629,"conditions":1435,"interventions":1436},[90],[15],[612,611,593],{"trials":1438,"activeCount":99},[],{"trials":1440,"activeCount":99},[],{"intervention":510,"totalTrials":278,"cells":1442},{"EARLY_PHASE1":1443,"PHASE1":1445,"PHASE2":1447,"PHASE3":1449,"PHASE4":1459,"NA":1461},{"trials":1444,"activeCount":99},[],{"trials":1446,"activeCount":99},[],{"trials":1448,"activeCount":99},[],{"trials":1450,"activeCount":99},[1451,1455],{"nctId":500,"briefTitle":501,"status":301,"phases":1452,"primaryCompletion":503,"completion":504,"start":505,"enrollment":506,"conditions":1453,"interventions":1454},[90],[508,31],[467,510],{"nctId":512,"briefTitle":513,"status":301,"phases":1456,"primaryCompletion":515,"completion":515,"start":516,"enrollment":517,"conditions":1457,"interventions":1458},[90],[519,250,520,521,522],[467,510],{"trials":1460,"activeCount":99},[],{"trials":1462,"activeCount":99},[],{"intervention":611,"totalTrials":278,"cells":1464},{"EARLY_PHASE1":1465,"PHASE1":1467,"PHASE2":1469,"PHASE3":1471,"PHASE4":1481,"NA":1483},{"trials":1466,"activeCount":99},[],{"trials":1468,"activeCount":99},[],{"trials":1470,"activeCount":99},[],{"trials":1472,"activeCount":99},[1473,1477],{"nctId":604,"briefTitle":605,"status":404,"phases":1474,"primaryCompletion":607,"completion":607,"start":608,"enrollment":506,"conditions":1475,"interventions":1476},[90],[15],[593,611,612],{"nctId":623,"briefTitle":624,"status":301,"phases":1478,"primaryCompletion":626,"completion":627,"start":628,"enrollment":629,"conditions":1479,"interventions":1480},[90],[15],[612,611,593],{"trials":1482,"activeCount":99},[],{"trials":1484,"activeCount":99},[],{"intervention":1486,"totalTrials":95,"cells":1487},"Olanzapine",{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1494,"PHASE4":1504,"NA":1506},{"trials":1489,"activeCount":99},[],{"trials":1491,"activeCount":99},[],{"trials":1493,"activeCount":99},[],{"trials":1495,"activeCount":99},[1496],{"nctId":1497,"briefTitle":1498,"status":404,"phases":1499,"primaryCompletion":1500,"completion":1500,"start":628,"enrollment":1501,"conditions":1502,"interventions":1503},"NCT00194064","Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine",[90],"2006-02",18,[15],[1486],{"trials":1505,"activeCount":99},[],{"trials":1507,"activeCount":99},[],{"intervention":1509,"totalTrials":95,"cells":1510},"Oxytocin",{"EARLY_PHASE1":1511,"PHASE1":1513,"PHASE2":1515,"PHASE3":1517,"PHASE4":1530,"NA":1532},{"trials":1512,"activeCount":99},[],{"trials":1514,"activeCount":99},[],{"trials":1516,"activeCount":99},[],{"trials":1518,"activeCount":99},[1519],{"nctId":1520,"briefTitle":1521,"status":301,"phases":1522,"primaryCompletion":920,"completion":920,"start":1523,"enrollment":1524,"conditions":1525,"interventions":1529},"NCT03138252","Study of the Effectiveness of Cervical Ripening Balloon With and Without Oxytocin",[90],"2014-11",180,[1526,1527,1528],"Cervical Ripening","Induction of Labor","Multiparity",[1509],{"trials":1531,"activeCount":99},[],{"trials":1533,"activeCount":99},[],{"intervention":1535,"totalTrials":95,"cells":1536},"IVM plus ALB",{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1541,"PHASE3":1543,"PHASE4":1557,"NA":1559},{"trials":1538,"activeCount":99},[],{"trials":1540,"activeCount":99},[],{"trials":1542,"activeCount":99},[],{"trials":1544,"activeCount":99},[1545],{"nctId":1546,"briefTitle":1547,"status":301,"phases":1548,"primaryCompletion":1549,"completion":1550,"start":1551,"enrollment":1552,"conditions":1553,"interventions":1555},"NCT02078024","Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana",[90],"2018-06","2018-06-25","2014-06",375,[1554],"Onchocerciasis",[1535,1556],"IVM",{"trials":1558,"activeCount":99},[],{"trials":1560,"activeCount":99},[],{"intervention":1556,"totalTrials":95,"cells":1562},{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1567,"PHASE3":1569,"PHASE4":1575,"NA":1577},{"trials":1564,"activeCount":99},[],{"trials":1566,"activeCount":99},[],{"trials":1568,"activeCount":99},[],{"trials":1570,"activeCount":99},[1571],{"nctId":1546,"briefTitle":1547,"status":301,"phases":1572,"primaryCompletion":1549,"completion":1550,"start":1551,"enrollment":1552,"conditions":1573,"interventions":1574},[90],[1554],[1535,1556],{"trials":1576,"activeCount":99},[],{"trials":1578,"activeCount":99},[],{"intervention":771,"totalTrials":95,"cells":1580},{"EARLY_PHASE1":1581,"PHASE1":1583,"PHASE2":1585,"PHASE3":1587,"PHASE4":1593,"NA":1595},{"trials":1582,"activeCount":99},[],{"trials":1584,"activeCount":99},[],{"trials":1586,"activeCount":99},[],{"trials":1588,"activeCount":99},[1589],{"nctId":760,"briefTitle":761,"status":762,"phases":1590,"primaryCompletion":764,"completion":765,"start":766,"enrollment":99,"conditions":1591,"interventions":1592},[90],[768,769],[771,749],{"trials":1594,"activeCount":99},[],{"trials":1596,"activeCount":99},[],{"intervention":1598,"totalTrials":95,"cells":1599},"Divalproex Sodium ER",{"EARLY_PHASE1":1600,"PHASE1":1602,"PHASE2":1604,"PHASE3":1606,"PHASE4":1617,"NA":1619},{"trials":1601,"activeCount":99},[],{"trials":1603,"activeCount":99},[],{"trials":1605,"activeCount":99},[],{"trials":1607,"activeCount":99},[1608],{"nctId":1609,"briefTitle":1610,"status":301,"phases":1611,"primaryCompletion":1612,"completion":727,"start":1613,"enrollment":1614,"conditions":1615,"interventions":1616},"NCT00194116","Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression",[90],"2007-10","2004-09",54,[15],[1598],{"trials":1618,"activeCount":99},[],{"trials":1620,"activeCount":99},[],{"intervention":1622,"totalTrials":95,"cells":1623},"Quetiapine XR",{"EARLY_PHASE1":1624,"PHASE1":1626,"PHASE2":1628,"PHASE3":1630,"PHASE4":1644,"NA":1646},{"trials":1625,"activeCount":99},[],{"trials":1627,"activeCount":99},[],{"trials":1629,"activeCount":99},[],{"trials":1631,"activeCount":99},[1632],{"nctId":1633,"briefTitle":1634,"status":301,"phases":1635,"primaryCompletion":1636,"completion":1636,"start":1637,"enrollment":1638,"conditions":1639,"interventions":1643},"NCT00671853","Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)",[90],"2011-03","2008-04",120,[15,1640,1641,1642],"Anxiety","Anxiety Disorders","Substance Use Disorders",[1622],{"trials":1645,"activeCount":99},[],{"trials":1647,"activeCount":99},[],{"intervention":1649,"totalTrials":95,"cells":1650},"Vitamin D control dose",{"EARLY_PHASE1":1651,"PHASE1":1653,"PHASE2":1655,"PHASE3":1657,"PHASE4":1669,"NA":1671},{"trials":1652,"activeCount":99},[],{"trials":1654,"activeCount":99},[],{"trials":1656,"activeCount":99},[],{"trials":1658,"activeCount":99},[1659],{"nctId":1660,"briefTitle":1661,"status":301,"phases":1662,"primaryCompletion":1663,"completion":1663,"start":1664,"enrollment":1665,"conditions":1666,"interventions":1667},"NCT01523496","Vitamin D Supplementation in HIV Youth",[89,90],"2016-08","2011-12",190,[29],[1649,1668],"Vitamin D supplementation-",{"trials":1670,"activeCount":99},[],{"trials":1672,"activeCount":99},[],{"intervention":1668,"totalTrials":95,"cells":1674},{"EARLY_PHASE1":1675,"PHASE1":1677,"PHASE2":1679,"PHASE3":1681,"PHASE4":1687,"NA":1689},{"trials":1676,"activeCount":99},[],{"trials":1678,"activeCount":99},[],{"trials":1680,"activeCount":99},[],{"trials":1682,"activeCount":99},[1683],{"nctId":1660,"briefTitle":1661,"status":301,"phases":1684,"primaryCompletion":1663,"completion":1663,"start":1664,"enrollment":1665,"conditions":1685,"interventions":1686},[89,90],[29],[1649,1668],{"trials":1688,"activeCount":99},[],{"trials":1690,"activeCount":99},[],{"intervention":1692,"totalTrials":95,"cells":1693},"Peppermint Oil",{"EARLY_PHASE1":1694,"PHASE1":1696,"PHASE2":1698,"PHASE3":1700,"PHASE4":1713,"NA":1715},{"trials":1695,"activeCount":99},[],{"trials":1697,"activeCount":99},[],{"trials":1699,"activeCount":99},[],{"trials":1701,"activeCount":99},[1702],{"nctId":1703,"briefTitle":1704,"status":404,"phases":1705,"primaryCompletion":1706,"completion":1706,"start":1707,"enrollment":1708,"conditions":1709,"interventions":1712},"NCT02588248","L-Menthol Injection as a Novel Technique During Colonoscopy",[90],"2017-05-30","2017-04-27",82,[1710,1711],"Colonic Polyps","Colon Cancer",[1692],{"trials":1714,"activeCount":99},[],{"trials":1716,"activeCount":99},[],{"intervention":1718,"totalTrials":95,"cells":1719},"Lamotrigine regular tablet formulation",{"EARLY_PHASE1":1720,"PHASE1":1722,"PHASE2":1724,"PHASE3":1726,"PHASE4":1738,"NA":1740},{"trials":1721,"activeCount":99},[],{"trials":1723,"activeCount":99},[],{"trials":1725,"activeCount":99},[],{"trials":1727,"activeCount":99},[1728],{"nctId":1729,"briefTitle":1730,"status":301,"phases":1731,"primaryCompletion":1732,"completion":1732,"start":1178,"enrollment":1733,"conditions":1734,"interventions":1736},"NCT00621842","Lamotrigine for Symptoms of Geriatric Bipolar Depression",[90],"2010-03",57,[15,1735],"Depression, Bipolar",[1718,1737],"Lamotrigine novel formulation",{"trials":1739,"activeCount":99},[],{"trials":1741,"activeCount":99},[],{"intervention":1737,"totalTrials":95,"cells":1743},{"EARLY_PHASE1":1744,"PHASE1":1746,"PHASE2":1748,"PHASE3":1750,"PHASE4":1756,"NA":1758},{"trials":1745,"activeCount":99},[],{"trials":1747,"activeCount":99},[],{"trials":1749,"activeCount":99},[],{"trials":1751,"activeCount":99},[1752],{"nctId":1729,"briefTitle":1730,"status":301,"phases":1753,"primaryCompletion":1732,"completion":1732,"start":1178,"enrollment":1733,"conditions":1754,"interventions":1755},[90],[15,1735],[1718,1737],{"trials":1757,"activeCount":99},[],{"trials":1759,"activeCount":99},[],{"intervention":1761,"totalTrials":95,"cells":1762},"Acetylsalicylic acid",{"EARLY_PHASE1":1763,"PHASE1":1765,"PHASE2":1767,"PHASE3":1769,"PHASE4":1780,"NA":1782},{"trials":1764,"activeCount":99},[],{"trials":1766,"activeCount":99},[],{"trials":1768,"activeCount":99},[],{"trials":1770,"activeCount":99},[1771],{"nctId":1772,"briefTitle":1773,"status":762,"phases":1774,"primaryCompletion":1775,"completion":1776,"start":921,"enrollment":99,"conditions":1777,"interventions":1779},"NCT02807441","Perioperative Bleeding and Aspirin Use in Spine Surgery",[90],"2019-07","2019-12",[1778,782],"Hemorrhage",[1761],{"trials":1781,"activeCount":99},[],{"trials":1783,"activeCount":99},[],{"intervention":1785,"totalTrials":95,"cells":1786},"Tamsulosin",{"EARLY_PHASE1":1787,"PHASE1":1789,"PHASE2":1791,"PHASE3":1793,"PHASE4":1807,"NA":1809},{"trials":1788,"activeCount":99},[],{"trials":1790,"activeCount":99},[],{"trials":1792,"activeCount":99},[],{"trials":1794,"activeCount":99},[1795],{"nctId":1796,"briefTitle":1797,"status":301,"phases":1798,"primaryCompletion":1799,"completion":1799,"start":1800,"enrollment":1801,"conditions":1802,"interventions":1806},"NCT03524339","Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery",[89,90],"2020-06-09","2018-08-01",132,[1803,1804,1805,1230],"Urinary Retention","Lower Urinary Tract Symptoms","Stress Urinary Incontinence",[1785],{"trials":1808,"activeCount":99},[],{"trials":1810,"activeCount":99},[],{"intervention":1812,"totalTrials":95,"cells":1813},"Rosuvastatin 10 mg. daily for 96 weeks",{"EARLY_PHASE1":1814,"PHASE1":1816,"PHASE2":1818,"PHASE3":1830,"PHASE4":1832,"NA":1834},{"trials":1815,"activeCount":99},[],{"trials":1817,"activeCount":99},[],{"trials":1819,"activeCount":99},[1820],{"nctId":1821,"briefTitle":1822,"status":301,"phases":1823,"primaryCompletion":1824,"completion":1824,"start":1825,"enrollment":1826,"conditions":1827,"interventions":1829},"NCT01218802","Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks",[89],"2014-05","2011-02",147,[29,1828],"Heart Disease",[1812],{"trials":1831,"activeCount":99},[],{"trials":1833,"activeCount":99},[],{"trials":1835,"activeCount":99},[],{"intervention":1837,"totalTrials":95,"cells":1838},"DDAVP",{"EARLY_PHASE1":1839,"PHASE1":1841,"PHASE2":1843,"PHASE3":1855,"PHASE4":1857,"NA":1859},{"trials":1840,"activeCount":99},[],{"trials":1842,"activeCount":99},[],{"trials":1844,"activeCount":99},[1845],{"nctId":1846,"briefTitle":1847,"status":404,"phases":1848,"primaryCompletion":1849,"completion":1849,"start":1850,"enrollment":1851,"conditions":1852,"interventions":1854},"NCT01982760","DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty",[89],"2015-06-25","2013-12",14,[1853],"Postoperative Ecchymosis",[1837],{"trials":1856,"activeCount":99},[],{"trials":1858,"activeCount":99},[],{"trials":1860,"activeCount":99},[],{"intervention":1862,"totalTrials":95,"cells":1863},"chondroitin sulfate",{"EARLY_PHASE1":1864,"PHASE1":1866,"PHASE2":1868,"PHASE3":1878,"PHASE4":1880,"NA":1882},{"trials":1865,"activeCount":99},[],{"trials":1867,"activeCount":99},[],{"trials":1869,"activeCount":99},[1870],{"nctId":1871,"briefTitle":1872,"status":762,"phases":1873,"primaryCompletion":1874,"completion":557,"start":567,"enrollment":99,"conditions":1875,"interventions":1877},"NCT01245088","Chondroitin Sulfate for Crohn's Disease",[88,89],"2012-03",[1876],"Crohn's Disease",[1862],{"trials":1879,"activeCount":99},[],{"trials":1881,"activeCount":99},[],{"trials":1883,"activeCount":99},[],{"intervention":1885,"totalTrials":95,"cells":1886},"Vitamin D",{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1891,"PHASE3":1903,"PHASE4":1905,"NA":1907},{"trials":1888,"activeCount":99},[],{"trials":1890,"activeCount":99},[],{"trials":1892,"activeCount":99},[1893],{"nctId":1894,"briefTitle":1895,"status":301,"phases":1896,"primaryCompletion":1897,"completion":1897,"start":1177,"enrollment":1898,"conditions":1899,"interventions":1902},"NCT01093417","Study of Vitamin D and Effect on Heart Disease and Insulin Resistance",[89],"2010-10",45,[1900,1901,29],"Human Immunodeficiency Virus (HIV)","Vitamin D Deficiency",[1885],{"trials":1904,"activeCount":99},[],{"trials":1906,"activeCount":99},[],{"trials":1908,"activeCount":99},[],{"intervention":1910,"totalTrials":95,"cells":1911},"Salsalate",{"EARLY_PHASE1":1912,"PHASE1":1914,"PHASE2":1916,"PHASE3":1929,"PHASE4":1931,"NA":1933},{"trials":1913,"activeCount":99},[],{"trials":1915,"activeCount":99},[],{"trials":1917,"activeCount":99},[1918],{"nctId":1919,"briefTitle":1920,"status":301,"phases":1921,"primaryCompletion":1922,"completion":1922,"start":1923,"enrollment":743,"conditions":1924,"interventions":1928},"NCT01046682","Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults",[89],"2009-07","2009-01",[1925,1926,26,1927],"HIV","Endothelial Dysfunction","Insulin Resistance",[1910],{"trials":1930,"activeCount":99},[],{"trials":1932,"activeCount":99},[],{"trials":1934,"activeCount":99},[],{"intervention":1936,"totalTrials":95,"cells":1937},"Allergen",{"EARLY_PHASE1":1938,"PHASE1":1940,"PHASE2":1942,"PHASE3":1955,"PHASE4":1957,"NA":1959},{"trials":1939,"activeCount":99},[],{"trials":1941,"activeCount":99},[],{"trials":1943,"activeCount":99},[1944],{"nctId":1945,"briefTitle":1946,"status":725,"phases":1947,"primaryCompletion":1948,"completion":1948,"start":304,"enrollment":1949,"conditions":1950,"interventions":1954},"NCT01878929","The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions",[88,89],"2014-04",245,[1951,1952,1953],"Allergic Rhinitis","Asthma","Allergic Conjunctivitis",[1936],{"trials":1956,"activeCount":99},[],{"trials":1958,"activeCount":99},[],{"trials":1960,"activeCount":99},[],{"intervention":1962,"totalTrials":95,"cells":1963},"Apremilast",{"EARLY_PHASE1":1964,"PHASE1":1966,"PHASE2":1968,"PHASE3":1979,"PHASE4":1981,"NA":1983},{"trials":1965,"activeCount":99},[],{"trials":1967,"activeCount":99},[],{"trials":1969,"activeCount":99},[1970],{"nctId":1971,"briefTitle":1972,"status":301,"phases":1973,"primaryCompletion":1974,"completion":1974,"start":1225,"enrollment":1975,"conditions":1976,"interventions":1978},"NCT03442088","Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast",[89],"2021-09-30",28,[1977],"Plaque Psoriasis",[1962],{"trials":1980,"activeCount":99},[],{"trials":1982,"activeCount":99},[],{"trials":1984,"activeCount":99},[],{"intervention":1986,"totalTrials":95,"cells":1987},"Lovaza",{"EARLY_PHASE1":1988,"PHASE1":1990,"PHASE2":1992,"PHASE3":2003,"PHASE4":2005,"NA":2007},{"trials":1989,"activeCount":99},[],{"trials":1991,"activeCount":99},[],{"trials":1993,"activeCount":99},[1994],{"nctId":1995,"briefTitle":1996,"status":301,"phases":1997,"primaryCompletion":1732,"completion":1998,"start":1999,"enrollment":2000,"conditions":2001,"interventions":2002},"NCT01001767","Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease",[89],"2010-06","2009-04",35,[29,1828],[1986],{"trials":2004,"activeCount":99},[],{"trials":2006,"activeCount":99},[],{"trials":2008,"activeCount":99},[],{"intervention":415,"totalTrials":95,"cells":2010},{"EARLY_PHASE1":2011,"PHASE1":2013,"PHASE2":2015,"PHASE3":2021,"PHASE4":2023,"NA":2025},{"trials":2012,"activeCount":99},[],{"trials":2014,"activeCount":99},[],{"trials":2016,"activeCount":99},[2017],{"nctId":402,"briefTitle":403,"status":404,"phases":2018,"primaryCompletion":406,"completion":406,"start":407,"enrollment":24,"conditions":2019,"interventions":2020},[89],[409,410,411,412],[393,414,415],{"trials":2022,"activeCount":99},[],{"trials":2024,"activeCount":99},[],{"trials":2026,"activeCount":99},[],{"intervention":2028,"totalTrials":95,"cells":2029},"CC-10004",{"EARLY_PHASE1":2030,"PHASE1":2032,"PHASE2":2034,"PHASE3":2044,"PHASE4":2046,"NA":2048},{"trials":2031,"activeCount":99},[],{"trials":2033,"activeCount":99},[],{"trials":2035,"activeCount":99},[2036],{"nctId":2037,"briefTitle":2038,"status":301,"phases":2039,"primaryCompletion":567,"completion":567,"start":2040,"enrollment":27,"conditions":2041,"interventions":2043},"NCT00869089","Safety and Efficacy of CC-10004 for Prurigo Nodularis",[89],"2008-09",[2042],"Prurigo Nodularis",[2028],{"trials":2045,"activeCount":99},[],{"trials":2047,"activeCount":99},[],{"trials":2049,"activeCount":99},[],{"intervention":2051,"totalTrials":95,"cells":2052},"Hypertonic saline",{"EARLY_PHASE1":2053,"PHASE1":2055,"PHASE2":2057,"PHASE3":2067,"PHASE4":2069,"NA":2071},{"trials":2054,"activeCount":99},[],{"trials":2056,"activeCount":99},[],{"trials":2058,"activeCount":99},[2059],{"nctId":2060,"briefTitle":2061,"status":301,"phases":2062,"primaryCompletion":1948,"completion":1824,"start":2063,"enrollment":1501,"conditions":2064,"interventions":2066},"NCT01945944","Nebulized Hypertonic Saline for Mechanically Ventilated Children",[88,89],"2013-10",[2065],"Respiratory Failure",[2051],{"trials":2068,"activeCount":99},[],{"trials":2070,"activeCount":99},[],{"trials":2072,"activeCount":99},[],{"intervention":2074,"totalTrials":95,"cells":2075},"Vitamin D3 or Placebo",{"EARLY_PHASE1":2076,"PHASE1":2078,"PHASE2":2080,"PHASE3":2091,"PHASE4":2093,"NA":2095},{"trials":2077,"activeCount":99},[],{"trials":2079,"activeCount":99},[],{"trials":2081,"activeCount":99},[2082],{"nctId":2083,"briefTitle":2084,"status":762,"phases":2085,"primaryCompletion":2086,"completion":2086,"start":2087,"enrollment":99,"conditions":2088,"interventions":2090},"NCT04489628","Tele-health Enabled Clinical Trial for COVID-19",[88,89],"2021-06-01","2020-08-01",[2089],"SARS-CoV Infection",[2074],{"trials":2092,"activeCount":99},[],{"trials":2094,"activeCount":99},[],{"trials":2096,"activeCount":99},[],{"intervention":2098,"totalTrials":95,"cells":2099},"Isotretinoin",{"EARLY_PHASE1":2100,"PHASE1":2102,"PHASE2":2104,"PHASE3":2114,"PHASE4":2116,"NA":2118},{"trials":2101,"activeCount":99},[],{"trials":2103,"activeCount":99},[],{"trials":2105,"activeCount":99},[2106],{"nctId":2107,"briefTitle":2108,"status":404,"phases":2109,"primaryCompletion":2110,"completion":2110,"start":407,"enrollment":1042,"conditions":2111,"interventions":2113},"NCT01560585","Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease",[88,89],"2014-08",[2112],"Alzheimer's Disease",[2098],{"trials":2115,"activeCount":99},[],{"trials":2117,"activeCount":99},[],{"trials":2119,"activeCount":99},[],{"intervention":2121,"totalTrials":95,"cells":2122},"GSNO",{"EARLY_PHASE1":2123,"PHASE1":2125,"PHASE2":2136,"PHASE3":2138,"PHASE4":2140,"NA":2142},{"trials":2124,"activeCount":99},[],{"trials":2126,"activeCount":99},[2127],{"nctId":2128,"briefTitle":2129,"status":762,"phases":2130,"primaryCompletion":2131,"completion":2131,"start":2132,"enrollment":99,"conditions":2133,"interventions":2135},"NCT04619602","Inhaled Treatment for Bronchopulmonary Dysplasia",[88],"2025-09-01","2025-08-01",[2134],"Bronchopulmonary Dysplasia",[2121],{"trials":2137,"activeCount":99},[],{"trials":2139,"activeCount":99},[],{"trials":2141,"activeCount":99},[],{"trials":2143,"activeCount":99},[],{"intervention":2145,"totalTrials":95,"cells":2146},"Mesenchymal Stem Cells",{"EARLY_PHASE1":2147,"PHASE1":2149,"PHASE2":2158,"PHASE3":2160,"PHASE4":2162,"NA":2164},{"trials":2148,"activeCount":99},[],{"trials":2150,"activeCount":99},[2151],{"nctId":2152,"briefTitle":2153,"status":301,"phases":2154,"primaryCompletion":2155,"completion":2155,"start":1663,"enrollment":1851,"conditions":2156,"interventions":2157},"NCT02866721","Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis",[88],"2020-08",[21],[2145],{"trials":2159,"activeCount":99},[],{"trials":2161,"activeCount":99},[],{"trials":2163,"activeCount":99},[],{"trials":2165,"activeCount":99},[],{"intervention":2167,"totalTrials":95,"cells":2168},"Buprenorphine",{"EARLY_PHASE1":2169,"PHASE1":2171,"PHASE2":2183,"PHASE3":2185,"PHASE4":2187,"NA":2189},{"trials":2170,"activeCount":99},[],{"trials":2172,"activeCount":99},[2173],{"nctId":2174,"briefTitle":2175,"status":404,"phases":2176,"primaryCompletion":2177,"completion":2177,"start":1227,"enrollment":2178,"conditions":2179,"interventions":2180},"NCT03268278","Efficacy of Buprenorphine on Postoperative Endodontic Analgesia",[88],"2018-07-01",10,[31],[2167,2181,2182],"Sterile saline","lidocaine, epinephrine",{"trials":2184,"activeCount":99},[],{"trials":2186,"activeCount":99},[],{"trials":2188,"activeCount":99},[],{"trials":2190,"activeCount":99},[],{"intervention":2181,"totalTrials":95,"cells":2192},{"EARLY_PHASE1":2193,"PHASE1":2195,"PHASE2":2201,"PHASE3":2203,"PHASE4":2205,"NA":2207},{"trials":2194,"activeCount":99},[],{"trials":2196,"activeCount":99},[2197],{"nctId":2174,"briefTitle":2175,"status":404,"phases":2198,"primaryCompletion":2177,"completion":2177,"start":1227,"enrollment":2178,"conditions":2199,"interventions":2200},[88],[31],[2167,2181,2182],{"trials":2202,"activeCount":99},[],{"trials":2204,"activeCount":99},[],{"trials":2206,"activeCount":99},[],{"trials":2208,"activeCount":99},[],{"intervention":2182,"totalTrials":95,"cells":2210},{"EARLY_PHASE1":2211,"PHASE1":2213,"PHASE2":2219,"PHASE3":2221,"PHASE4":2223,"NA":2225},{"trials":2212,"activeCount":99},[],{"trials":2214,"activeCount":99},[2215],{"nctId":2174,"briefTitle":2175,"status":404,"phases":2216,"primaryCompletion":2177,"completion":2177,"start":1227,"enrollment":2178,"conditions":2217,"interventions":2218},[88],[31],[2167,2181,2182],{"trials":2220,"activeCount":99},[],{"trials":2222,"activeCount":99},[],{"trials":2224,"activeCount":99},[],{"trials":2226,"activeCount":99},[],{"intervention":2228,"totalTrials":95,"cells":2229},"Ivermectin, Diethylcarbamazine Albendazole",{"EARLY_PHASE1":2230,"PHASE1":2232,"PHASE2":2244,"PHASE3":2246,"PHASE4":2248,"NA":2250},{"trials":2231,"activeCount":99},[],{"trials":2233,"activeCount":99},[2234],{"nctId":2235,"briefTitle":2236,"status":301,"phases":2237,"primaryCompletion":2238,"completion":2239,"start":2240,"enrollment":1228,"conditions":2241,"interventions":2243},"NCT02845713","Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)",[88],"2016-06","2016-06-04","2016-04-17",[2242],"Wuchereria Bancrofti Infection",[2228],{"trials":2245,"activeCount":99},[],{"trials":2247,"activeCount":99},[],{"trials":2249,"activeCount":99},[],{"trials":2251,"activeCount":99},[],{"intervention":2253,"totalTrials":95,"cells":2254},"AlloMEM™",{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2267,"PHASE3":2269,"PHASE4":2271,"NA":2273},{"trials":2256,"activeCount":99},[],{"trials":2258,"activeCount":99},[2259],{"nctId":2260,"briefTitle":2261,"status":301,"phases":2262,"primaryCompletion":2263,"completion":2263,"start":1177,"enrollment":2178,"conditions":2264,"interventions":2266},"NCT01113736","Pilot Study Evaluating the Efficacy of AlloMEM After Loop Ileostomy",[88],"2012-07",[1711,2265],"Rectal Cancer",[2253],{"trials":2268,"activeCount":99},[],{"trials":2270,"activeCount":99},[],{"trials":2272,"activeCount":99},[],{"trials":2274,"activeCount":99},[],{"intervention":2276,"totalTrials":95,"cells":2277},"Ipratropium",{"EARLY_PHASE1":2278,"PHASE1":2280,"PHASE2":2295,"PHASE3":2297,"PHASE4":2299,"NA":2301},{"trials":2279,"activeCount":99},[],{"trials":2281,"activeCount":99},[2282],{"nctId":2283,"briefTitle":2284,"status":301,"phases":2285,"primaryCompletion":2286,"completion":2287,"start":2288,"enrollment":112,"conditions":2289,"interventions":2291},"NCT02872597","Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus",[88],"2018-08-15","2018-08-16","2016-09-05",[2290],"Status Asthmaticus",[2276,2292,2293,2294],"0.9% Sodium Chloride","Albuterol","corticosteroids",{"trials":2296,"activeCount":99},[],{"trials":2298,"activeCount":99},[],{"trials":2300,"activeCount":99},[],{"trials":2302,"activeCount":99},[],{"intervention":2292,"totalTrials":95,"cells":2304},{"EARLY_PHASE1":2305,"PHASE1":2307,"PHASE2":2313,"PHASE3":2315,"PHASE4":2317,"NA":2319},{"trials":2306,"activeCount":99},[],{"trials":2308,"activeCount":99},[2309],{"nctId":2283,"briefTitle":2284,"status":301,"phases":2310,"primaryCompletion":2286,"completion":2287,"start":2288,"enrollment":112,"conditions":2311,"interventions":2312},[88],[2290],[2276,2292,2293,2294],{"trials":2314,"activeCount":99},[],{"trials":2316,"activeCount":99},[],{"trials":2318,"activeCount":99},[],{"trials":2320,"activeCount":99},[],{"intervention":2293,"totalTrials":95,"cells":2322},{"EARLY_PHASE1":2323,"PHASE1":2325,"PHASE2":2331,"PHASE3":2333,"PHASE4":2335,"NA":2337},{"trials":2324,"activeCount":99},[],{"trials":2326,"activeCount":99},[2327],{"nctId":2283,"briefTitle":2284,"status":301,"phases":2328,"primaryCompletion":2286,"completion":2287,"start":2288,"enrollment":112,"conditions":2329,"interventions":2330},[88],[2290],[2276,2292,2293,2294],{"trials":2332,"activeCount":99},[],{"trials":2334,"activeCount":99},[],{"trials":2336,"activeCount":99},[],{"trials":2338,"activeCount":99},[],{"intervention":2294,"totalTrials":95,"cells":2340},{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2349,"PHASE3":2351,"PHASE4":2353,"NA":2355},{"trials":2342,"activeCount":99},[],{"trials":2344,"activeCount":99},[2345],{"nctId":2283,"briefTitle":2284,"status":301,"phases":2346,"primaryCompletion":2286,"completion":2287,"start":2288,"enrollment":112,"conditions":2347,"interventions":2348},[88],[2290],[2276,2292,2293,2294],{"trials":2350,"activeCount":99},[],{"trials":2352,"activeCount":99},[],{"trials":2354,"activeCount":99},[],{"trials":2356,"activeCount":99},[],{"intervention":2358,"totalTrials":95,"cells":2359},"Sodium Bicarbonate",{"EARLY_PHASE1":2360,"PHASE1":2362,"PHASE2":2375,"PHASE3":2377,"PHASE4":2379,"NA":2381},{"trials":2361,"activeCount":99},[],{"trials":2363,"activeCount":99},[2364],{"nctId":2365,"briefTitle":2366,"status":404,"phases":2367,"primaryCompletion":2368,"completion":2368,"start":2369,"enrollment":24,"conditions":2370,"interventions":2374},"NCT01894594","Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease",[88],"2019-03","2013-06",[2371,2372,2373],"Sickle Cell Anemia","Chronic Kidney Disease","Metabolic Acidosis",[2358],{"trials":2376,"activeCount":99},[],{"trials":2378,"activeCount":99},[],{"trials":2380,"activeCount":99},[],{"trials":2382,"activeCount":99},[],{"intervention":2384,"totalTrials":95,"cells":2385},"OnabotulinumtoxinA",{"EARLY_PHASE1":2386,"PHASE1":2388,"PHASE2":2402,"PHASE3":2404,"PHASE4":2406,"NA":2408},{"trials":2387,"activeCount":99},[],{"trials":2389,"activeCount":99},[2390],{"nctId":2391,"briefTitle":2392,"status":301,"phases":2393,"primaryCompletion":2394,"completion":2395,"start":2396,"enrollment":2178,"conditions":2397,"interventions":2401},"NCT02173405","Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic Pain",[88],"2015-09-01","2016-09-01","2014-08-01",[2398,2399,2400],"Myofascial Pain Syndromes","Myofascial Trigger Point Pain","Trigger Point Pain, Myofascial",[2384],{"trials":2403,"activeCount":99},[],{"trials":2405,"activeCount":99},[],{"trials":2407,"activeCount":99},[],{"trials":2409,"activeCount":99},[],{"intervention":2411,"totalTrials":95,"cells":2412},"Zinc Gluconate",{"EARLY_PHASE1":2413,"PHASE1":2426,"PHASE2":2428,"PHASE3":2430,"PHASE4":2432,"NA":2434},{"trials":2414,"activeCount":99},[2415],{"nctId":2416,"briefTitle":2417,"status":301,"phases":2418,"primaryCompletion":2419,"completion":2419,"start":2420,"enrollment":2421,"conditions":2422,"interventions":2425},"NCT05085834","Zinc Effect on Inflammation and Cardiovascular Risk in HIV",[87],"2024-08-02","2020-01-22",95,[26,2423,2424],"Cardiovascular Diseases","Zinc Deficiency",[2411],{"trials":2427,"activeCount":99},[],{"trials":2429,"activeCount":99},[],{"trials":2431,"activeCount":99},[],{"trials":2433,"activeCount":99},[],{"trials":2435,"activeCount":99},[],{"intervention":2437,"totalTrials":95,"cells":2438},"MSC Treatment group 1",{"EARLY_PHASE1":2439,"PHASE1":2451,"PHASE2":2453,"PHASE3":2455,"PHASE4":2457,"NA":2459},{"trials":2440,"activeCount":99},[2441],{"nctId":2442,"briefTitle":2443,"status":762,"phases":2444,"primaryCompletion":1974,"completion":2445,"start":2446,"enrollment":99,"conditions":2447,"interventions":2449},"NCT03692221","Mesenchymal Stem Cells for Lumbar Degenerative Disc Disease",[87],"2022-09-30","2019-06",[2448],"Disc Degeneration",[2437,2450],"MSC Treatment group 2",{"trials":2452,"activeCount":99},[],{"trials":2454,"activeCount":99},[],{"trials":2456,"activeCount":99},[],{"trials":2458,"activeCount":99},[],{"trials":2460,"activeCount":99},[],{"intervention":2450,"totalTrials":95,"cells":2462},{"EARLY_PHASE1":2463,"PHASE1":2469,"PHASE2":2471,"PHASE3":2473,"PHASE4":2475,"NA":2477},{"trials":2464,"activeCount":99},[2465],{"nctId":2442,"briefTitle":2443,"status":762,"phases":2466,"primaryCompletion":1974,"completion":2445,"start":2446,"enrollment":99,"conditions":2467,"interventions":2468},[87],[2448],[2437,2450],{"trials":2470,"activeCount":99},[],{"trials":2472,"activeCount":99},[],{"trials":2474,"activeCount":99},[],{"trials":2476,"activeCount":99},[],{"trials":2478,"activeCount":99},[],{"intervention":481,"totalTrials":95,"cells":2480},{"EARLY_PHASE1":2481,"PHASE1":2487,"PHASE2":2489,"PHASE3":2491,"PHASE4":2493,"NA":2495},{"trials":2482,"activeCount":99},[2483],{"nctId":472,"briefTitle":473,"status":301,"phases":2484,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":2485,"interventions":2486},[87],[479],[481,467],{"trials":2488,"activeCount":99},[],{"trials":2490,"activeCount":99},[],{"trials":2492,"activeCount":99},[],{"trials":2494,"activeCount":99},[],{"trials":2496,"activeCount":99},[],{"intervention":2498,"totalTrials":95,"cells":2499},"Secretin Synthetic Human",{"EARLY_PHASE1":2500,"PHASE1":2510,"PHASE2":2512,"PHASE3":2514,"PHASE4":2516,"NA":2518},{"trials":2501,"activeCount":99},[2502],{"nctId":2503,"briefTitle":2504,"status":762,"phases":2505,"primaryCompletion":1664,"completion":558,"start":2506,"enrollment":99,"conditions":2507,"interventions":2509},"NCT01371240","Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity",[87],"2011-06",[2508],"Pancreas Cancer",[2498],{"trials":2511,"activeCount":99},[],{"trials":2513,"activeCount":99},[],{"trials":2515,"activeCount":99},[],{"trials":2517,"activeCount":99},[],{"trials":2519,"activeCount":99},[],{"intervention":2521,"totalTrials":95,"cells":2522},"Valchlor",{"EARLY_PHASE1":2523,"PHASE1":2534,"PHASE2":2536,"PHASE3":2538,"PHASE4":2540,"NA":2542},{"trials":2524,"activeCount":99},[2525],{"nctId":2526,"briefTitle":2527,"status":301,"phases":2528,"primaryCompletion":376,"completion":376,"start":2529,"enrollment":2530,"conditions":2531,"interventions":2533},"NCT02968446","Effect of Vitamin D After Application With Valchlor",[87],"2016-11-17",33,[2532],"Skin Irritation",[2521],{"trials":2535,"activeCount":99},[],{"trials":2537,"activeCount":99},[],{"trials":2539,"activeCount":99},[],{"trials":2541,"activeCount":99},[],{"trials":2543,"activeCount":99},[],{"intervention":710,"totalTrials":34,"cells":2545},{"EARLY_PHASE1":2546,"PHASE1":2548,"PHASE2":2550,"PHASE3":2552,"PHASE4":2554,"NA":2564},{"trials":2547,"activeCount":99},[],{"trials":2549,"activeCount":99},[],{"trials":2551,"activeCount":99},[],{"trials":2553,"activeCount":99},[],{"trials":2555,"activeCount":99},[2556,2560],{"nctId":699,"briefTitle":700,"status":301,"phases":2557,"primaryCompletion":702,"completion":702,"start":703,"enrollment":203,"conditions":2558,"interventions":2559},[91],[705,706,707,708],[710,414],{"nctId":1340,"briefTitle":1341,"status":301,"phases":2561,"primaryCompletion":1343,"completion":1343,"start":531,"enrollment":1344,"conditions":2562,"interventions":2563},[91],[1346,1347,1348],[710,1327],{"trials":2565,"activeCount":99},[2566,2575],{"nctId":2567,"briefTitle":2568,"status":301,"phases":2569,"primaryCompletion":2110,"completion":2110,"start":2263,"enrollment":665,"conditions":2570,"interventions":2572},"NCT01731782","Evaluation of a TAP Block Given During Laparoscopic Colorectal Surgery to Help Control Pain",[92],[2571],"Colorectal Disease",[2573,2574],"bupivacaine","normal saline placebo",{"nctId":2576,"briefTitle":2577,"status":301,"phases":2578,"primaryCompletion":627,"completion":627,"start":2579,"enrollment":269,"conditions":2580,"interventions":2582},"NCT00472134","Laparoscopic Ventral Hernia Repair With Elastomeric Pain Pump",[92],"2005-12",[2581],"Hernia, Ventral",[2573],{"intervention":2584,"totalTrials":34,"cells":2585},"Pioglitazone",{"EARLY_PHASE1":2586,"PHASE1":2588,"PHASE2":2590,"PHASE3":2592,"PHASE4":2594,"NA":2615},{"trials":2587,"activeCount":99},[],{"trials":2589,"activeCount":99},[],{"trials":2591,"activeCount":99},[],{"trials":2593,"activeCount":99},[],{"trials":2595,"activeCount":99},[2596,2606],{"nctId":2597,"briefTitle":2598,"status":301,"phases":2599,"primaryCompletion":304,"completion":304,"start":2600,"enrollment":2601,"conditions":2602,"interventions":2605},"NCT00835120","Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance",[91],"2009-03",34,[2603,2604,1927],"Metabolic Syndrome","Bipolar Depression",[2584],{"nctId":2607,"briefTitle":2608,"status":404,"phases":2609,"primaryCompletion":2610,"completion":2610,"start":2611,"enrollment":2612,"conditions":2613,"interventions":2614},"NCT01717040","Pioglitazone for the Treatment of Bipolar Depression",[91],"2016-03","2012-09",37,[15,1927],[2584],{"trials":2616,"activeCount":99},[2617,2627],{"nctId":2618,"briefTitle":2619,"status":301,"phases":2620,"primaryCompletion":2621,"completion":2621,"start":2622,"enrollment":180,"conditions":2623,"interventions":2624},"NCT00531882","Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers",[92],"2009-02","2007-09",[21],[2584,2625,2626],"Simvastatin","Ibuprofen",{"nctId":2628,"briefTitle":2629,"status":301,"phases":2630,"primaryCompletion":2631,"completion":577,"start":2632,"enrollment":2633,"conditions":2634,"interventions":2635},"NCT00322868","Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease",[92],"2006-12","2006-04",21,[21],[2636],"pioglitazone",{"intervention":2638,"totalTrials":1042,"cells":2639},"Ivermectin",{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2656,"PHASE4":2667,"NA":2669},{"trials":2641,"activeCount":99},[],{"trials":2643,"activeCount":99},[],{"trials":2645,"activeCount":99},[2646],{"nctId":2647,"briefTitle":2648,"status":301,"phases":2649,"primaryCompletion":1343,"completion":1549,"start":1824,"enrollment":2650,"conditions":2651,"interventions":2653},"NCT01975441","Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa",[89],182,[2652],"Lymphatic Filariasis",[2654,2655,2638],"Diethylcarbamazine","Albendazole",{"trials":2657,"activeCount":99},[2658],{"nctId":2659,"briefTitle":2660,"status":301,"phases":2661,"primaryCompletion":2662,"completion":2663,"start":407,"enrollment":2664,"conditions":2665,"interventions":2666},"NCT03238131","IVM Alone vs ALB + IVM Against Onchocerciasis",[90],"2015-04","2016-10",272,[1554],[2638,2655],{"trials":2668,"activeCount":99},[],{"trials":2670,"activeCount":99},[2671],{"nctId":2672,"briefTitle":2673,"status":301,"phases":2674,"primaryCompletion":2675,"completion":2676,"start":638,"enrollment":2677,"conditions":2678,"interventions":2679},"NCT02974049","Lymphatic Filariasis (LF) in Ivory Coast",[92],"2018-09","2018-09-25",189,[2652],[2655,2638,2654],{"intervention":2655,"totalTrials":1042,"cells":2681},{"EARLY_PHASE1":2682,"PHASE1":2684,"PHASE2":2686,"PHASE3":2692,"PHASE4":2698,"NA":2700},{"trials":2683,"activeCount":99},[],{"trials":2685,"activeCount":99},[],{"trials":2687,"activeCount":99},[2688],{"nctId":2647,"briefTitle":2648,"status":301,"phases":2689,"primaryCompletion":1343,"completion":1549,"start":1824,"enrollment":2650,"conditions":2690,"interventions":2691},[89],[2652],[2654,2655,2638],{"trials":2693,"activeCount":99},[2694],{"nctId":2659,"briefTitle":2660,"status":301,"phases":2695,"primaryCompletion":2662,"completion":2663,"start":407,"enrollment":2664,"conditions":2696,"interventions":2697},[90],[1554],[2638,2655],{"trials":2699,"activeCount":99},[],{"trials":2701,"activeCount":99},[2702],{"nctId":2672,"briefTitle":2673,"status":301,"phases":2703,"primaryCompletion":2675,"completion":2676,"start":638,"enrollment":2677,"conditions":2704,"interventions":2705},[92],[2652],[2655,2638,2654],{"intervention":2654,"totalTrials":278,"cells":2707},{"EARLY_PHASE1":2708,"PHASE1":2710,"PHASE2":2712,"PHASE3":2718,"PHASE4":2720,"NA":2722},{"trials":2709,"activeCount":99},[],{"trials":2711,"activeCount":99},[],{"trials":2713,"activeCount":99},[2714],{"nctId":2647,"briefTitle":2648,"status":301,"phases":2715,"primaryCompletion":1343,"completion":1549,"start":1824,"enrollment":2650,"conditions":2716,"interventions":2717},[89],[2652],[2654,2655,2638],{"trials":2719,"activeCount":99},[],{"trials":2721,"activeCount":99},[],{"trials":2723,"activeCount":99},[2724],{"nctId":2672,"briefTitle":2673,"status":301,"phases":2725,"primaryCompletion":2675,"completion":2676,"start":638,"enrollment":2677,"conditions":2726,"interventions":2727},[92],[2652],[2655,2638,2654],{"intervention":308,"totalTrials":95,"cells":2729},{"EARLY_PHASE1":2730,"PHASE1":2732,"PHASE2":2734,"PHASE3":2736,"PHASE4":2738,"NA":2740},{"trials":2731,"activeCount":99},[],{"trials":2733,"activeCount":99},[],{"trials":2735,"activeCount":99},[],{"trials":2737,"activeCount":99},[],{"trials":2739,"activeCount":99},[],{"trials":2741,"activeCount":99},[2742],{"nctId":299,"briefTitle":300,"status":301,"phases":2743,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":2744,"interventions":2745},[],[23,26],[308,65,309,310,311],{"intervention":309,"totalTrials":95,"cells":2747},{"EARLY_PHASE1":2748,"PHASE1":2750,"PHASE2":2752,"PHASE3":2754,"PHASE4":2756,"NA":2758},{"trials":2749,"activeCount":99},[],{"trials":2751,"activeCount":99},[],{"trials":2753,"activeCount":99},[],{"trials":2755,"activeCount":99},[],{"trials":2757,"activeCount":99},[],{"trials":2759,"activeCount":99},[2760],{"nctId":299,"briefTitle":300,"status":301,"phases":2761,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":2762,"interventions":2763},[],[23,26],[308,65,309,310,311],{"intervention":310,"totalTrials":95,"cells":2765},{"EARLY_PHASE1":2766,"PHASE1":2768,"PHASE2":2770,"PHASE3":2772,"PHASE4":2774,"NA":2776},{"trials":2767,"activeCount":99},[],{"trials":2769,"activeCount":99},[],{"trials":2771,"activeCount":99},[],{"trials":2773,"activeCount":99},[],{"trials":2775,"activeCount":99},[],{"trials":2777,"activeCount":99},[2778],{"nctId":299,"briefTitle":300,"status":301,"phases":2779,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":2780,"interventions":2781},[],[23,26],[308,65,309,310,311],{"intervention":311,"totalTrials":95,"cells":2783},{"EARLY_PHASE1":2784,"PHASE1":2786,"PHASE2":2788,"PHASE3":2790,"PHASE4":2792,"NA":2794},{"trials":2785,"activeCount":99},[],{"trials":2787,"activeCount":99},[],{"trials":2789,"activeCount":99},[],{"trials":2791,"activeCount":99},[],{"trials":2793,"activeCount":99},[],{"trials":2795,"activeCount":99},[2796],{"nctId":299,"briefTitle":300,"status":301,"phases":2797,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":2798,"interventions":2799},[],[23,26],[308,65,309,310,311],{"intervention":2801,"totalTrials":95,"cells":2802},"Vasopressins",{"EARLY_PHASE1":2803,"PHASE1":2805,"PHASE2":2807,"PHASE3":2809,"PHASE4":2811,"NA":2813},{"trials":2804,"activeCount":99},[],{"trials":2806,"activeCount":99},[],{"trials":2808,"activeCount":99},[],{"trials":2810,"activeCount":99},[],{"trials":2812,"activeCount":99},[],{"trials":2814,"activeCount":99},[2815],{"nctId":2816,"briefTitle":2817,"status":762,"phases":2818,"primaryCompletion":2819,"start":2820,"enrollment":99,"conditions":2821,"interventions":2823},"NCT02377492","Paracervical Vasopressin Injection Compared With Intramyometrial Vasopressin in Abdominal Myomectomy",[92],"2017-03","2015-03",[2822],"Myoma",[2801],{"intervention":2825,"totalTrials":95,"cells":2826},"Clomiphene",{"EARLY_PHASE1":2827,"PHASE1":2829,"PHASE2":2831,"PHASE3":2833,"PHASE4":2835,"NA":2837},{"trials":2828,"activeCount":99},[],{"trials":2830,"activeCount":99},[],{"trials":2832,"activeCount":99},[],{"trials":2834,"activeCount":99},[],{"trials":2836,"activeCount":99},[],{"trials":2838,"activeCount":99},[2839],{"nctId":2840,"briefTitle":2841,"status":762,"phases":2842,"primaryCompletion":2819,"start":2820,"enrollment":99,"conditions":2843,"interventions":2845},"NCT02377479","Endocrinology Profile in Patients Undergoing Clomiphene, Letrozole, and Combination Clomiphene and Letrozole Cycles",[92],[2844],"Infertility",[2825,2846],"Letrozole",{"intervention":2846,"totalTrials":95,"cells":2848},{"EARLY_PHASE1":2849,"PHASE1":2851,"PHASE2":2853,"PHASE3":2855,"PHASE4":2857,"NA":2859},{"trials":2850,"activeCount":99},[],{"trials":2852,"activeCount":99},[],{"trials":2854,"activeCount":99},[],{"trials":2856,"activeCount":99},[],{"trials":2858,"activeCount":99},[],{"trials":2860,"activeCount":99},[2861],{"nctId":2840,"briefTitle":2841,"status":762,"phases":2862,"primaryCompletion":2819,"start":2820,"enrollment":99,"conditions":2863,"interventions":2864},[92],[2844],[2825,2846],{"intervention":2866,"totalTrials":95,"cells":2867},"Halo Oral Spray",{"EARLY_PHASE1":2868,"PHASE1":2870,"PHASE2":2872,"PHASE3":2874,"PHASE4":2876,"NA":2878},{"trials":2869,"activeCount":99},[],{"trials":2871,"activeCount":99},[],{"trials":2873,"activeCount":99},[],{"trials":2875,"activeCount":99},[],{"trials":2877,"activeCount":99},[],{"trials":2879,"activeCount":99},[2880],{"nctId":2881,"briefTitle":2882,"status":301,"phases":2883,"primaryCompletion":2369,"completion":2369,"start":2884,"enrollment":269,"conditions":2885,"interventions":2887},"NCT02644135","A Pilot Study of the Safety, Tolerability, and Effectiveness of Halo",[92],"2013-01",[2886],"Healthy",[2866,2888],"Halo Placebo",{"intervention":2888,"totalTrials":95,"cells":2890},{"EARLY_PHASE1":2891,"PHASE1":2893,"PHASE2":2895,"PHASE3":2897,"PHASE4":2899,"NA":2901},{"trials":2892,"activeCount":99},[],{"trials":2894,"activeCount":99},[],{"trials":2896,"activeCount":99},[],{"trials":2898,"activeCount":99},[],{"trials":2900,"activeCount":99},[],{"trials":2902,"activeCount":99},[2903],{"nctId":2881,"briefTitle":2882,"status":301,"phases":2904,"primaryCompletion":2369,"completion":2369,"start":2884,"enrollment":269,"conditions":2905,"interventions":2906},[92],[2886],[2866,2888],{"intervention":2908,"totalTrials":95,"cells":2909},"Infliximab",{"EARLY_PHASE1":2910,"PHASE1":2912,"PHASE2":2914,"PHASE3":2916,"PHASE4":2918,"NA":2920},{"trials":2911,"activeCount":99},[],{"trials":2913,"activeCount":99},[],{"trials":2915,"activeCount":99},[],{"trials":2917,"activeCount":99},[],{"trials":2919,"activeCount":99},[],{"trials":2921,"activeCount":99},[2922],{"nctId":2923,"briefTitle":2924,"status":301,"phases":2925,"primaryCompletion":2926,"completion":2927,"start":2928,"enrollment":278,"conditions":2929,"interventions":2933},"NCT00791557","Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease",[92],"2009-12","2010-02","2008-10",[2930,1876,2931,2932],"Pyoderma Gangrenosum","Ulcerative Colitis","Inflammatory Bowel Disease",[2908],{"intervention":2935,"totalTrials":95,"cells":2936},"Bolus 10mL 0.25% bupivacaine\u002Fep 1:600,000; infusion 10mL\u002Fhour 0.25% bupivacaine and epi 1:800,000",{"EARLY_PHASE1":2937,"PHASE1":2939,"PHASE2":2941,"PHASE3":2943,"PHASE4":2945,"NA":2947},{"trials":2938,"activeCount":99},[],{"trials":2940,"activeCount":99},[],{"trials":2942,"activeCount":99},[],{"trials":2944,"activeCount":99},[],{"trials":2946,"activeCount":99},[],{"trials":2948,"activeCount":99},[2949],{"nctId":2950,"briefTitle":2951,"status":762,"phases":2952,"primaryCompletion":2953,"completion":2953,"start":557,"enrollment":99,"conditions":2954,"interventions":2957},"NCT01497509","Intrapartum Epidural Fentanyl and Breastfeeding in the Immediate Postpartum Period: a Randomized, Controlled, Double-blinded Study",[92],"2012-11",[2955,2956],"Neonatal Neurobehavior","Breastfeeding Outcomes",[2935,2958,2959,2960],"Bolus 10mL 0.25% bupivacaine\u002F epinephrine 1:600,000;infusion 10mL\u002Fhour 0.25% bupivacaine, 2 mcg\u002FmL fentanyl, and epinephrine 1:800,000","Bolus 10mL 0.25% bupivacaine, 10mcg\u002FmL fentanyl, and epi 1:600,000; infusion 10mL\u002Fhour 0.25% bupivacaine, 2.5 mcg\u002FmL fentanyl, and epi 1:800,000","Bolus 10mL 0.25% bupivacaine, 5 mcg\u002FmL fentanyl, and epi 1:600,000; infusion 10mL\u002Fhour 0.25% bupivacaine, 3.5 mcg\u002FmL fentanyl, and epi 1:800,000",{"intervention":2958,"totalTrials":95,"cells":2962},{"EARLY_PHASE1":2963,"PHASE1":2965,"PHASE2":2967,"PHASE3":2969,"PHASE4":2971,"NA":2973},{"trials":2964,"activeCount":99},[],{"trials":2966,"activeCount":99},[],{"trials":2968,"activeCount":99},[],{"trials":2970,"activeCount":99},[],{"trials":2972,"activeCount":99},[],{"trials":2974,"activeCount":99},[2975],{"nctId":2950,"briefTitle":2951,"status":762,"phases":2976,"primaryCompletion":2953,"completion":2953,"start":557,"enrollment":99,"conditions":2977,"interventions":2978},[92],[2955,2956],[2935,2958,2959,2960],{"intervention":2959,"totalTrials":95,"cells":2980},{"EARLY_PHASE1":2981,"PHASE1":2983,"PHASE2":2985,"PHASE3":2987,"PHASE4":2989,"NA":2991},{"trials":2982,"activeCount":99},[],{"trials":2984,"activeCount":99},[],{"trials":2986,"activeCount":99},[],{"trials":2988,"activeCount":99},[],{"trials":2990,"activeCount":99},[],{"trials":2992,"activeCount":99},[2993],{"nctId":2950,"briefTitle":2951,"status":762,"phases":2994,"primaryCompletion":2953,"completion":2953,"start":557,"enrollment":99,"conditions":2995,"interventions":2996},[92],[2955,2956],[2935,2958,2959,2960],{"intervention":2960,"totalTrials":95,"cells":2998},{"EARLY_PHASE1":2999,"PHASE1":3001,"PHASE2":3003,"PHASE3":3005,"PHASE4":3007,"NA":3009},{"trials":3000,"activeCount":99},[],{"trials":3002,"activeCount":99},[],{"trials":3004,"activeCount":99},[],{"trials":3006,"activeCount":99},[],{"trials":3008,"activeCount":99},[],{"trials":3010,"activeCount":99},[3011],{"nctId":2950,"briefTitle":2951,"status":762,"phases":3012,"primaryCompletion":2953,"completion":2953,"start":557,"enrollment":99,"conditions":3013,"interventions":3014},[92],[2955,2956],[2935,2958,2959,2960],{"intervention":3016,"totalTrials":95,"cells":3017},"[68Ga]PSMA",{"EARLY_PHASE1":3018,"PHASE1":3020,"PHASE2":3022,"PHASE3":3024,"PHASE4":3026,"NA":3028},{"trials":3019,"activeCount":99},[],{"trials":3021,"activeCount":99},[],{"trials":3023,"activeCount":99},[],{"trials":3025,"activeCount":99},[],{"trials":3027,"activeCount":99},[],{"trials":3029,"activeCount":99},[3030],{"nctId":3031,"briefTitle":3032,"status":301,"phases":3033,"primaryCompletion":3034,"completion":3034,"start":3035,"enrollment":425,"conditions":3036,"interventions":3038},"NCT05527483","Digital PET\u002FCT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients",[],"2022-10-10","2022-04-21",[3037],"Prostate Cancer",[3016,3039],"Flourine-18 [F-18] Sodium Fluoride",{"intervention":3039,"totalTrials":95,"cells":3041},{"EARLY_PHASE1":3042,"PHASE1":3044,"PHASE2":3046,"PHASE3":3048,"PHASE4":3050,"NA":3052},{"trials":3043,"activeCount":99},[],{"trials":3045,"activeCount":99},[],{"trials":3047,"activeCount":99},[],{"trials":3049,"activeCount":99},[],{"trials":3051,"activeCount":99},[],{"trials":3053,"activeCount":99},[3054],{"nctId":3031,"briefTitle":3032,"status":301,"phases":3055,"primaryCompletion":3034,"completion":3034,"start":3035,"enrollment":425,"conditions":3056,"interventions":3057},[],[3037],[3016,3039],{"intervention":3059,"totalTrials":95,"cells":3060},"haloperidol decanoate",{"EARLY_PHASE1":3061,"PHASE1":3063,"PHASE2":3065,"PHASE3":3067,"PHASE4":3069,"NA":3071},{"trials":3062,"activeCount":99},[],{"trials":3064,"activeCount":99},[],{"trials":3066,"activeCount":99},[],{"trials":3068,"activeCount":99},[],{"trials":3070,"activeCount":99},[],{"trials":3072,"activeCount":99},[3073],{"nctId":3074,"briefTitle":3075,"status":301,"phases":3076,"primaryCompletion":829,"completion":829,"start":1998,"enrollment":112,"conditions":3077,"interventions":3079},"NCT01152697","Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic",[92],[3078],"Patient Noncompliance",[3059,3080],"haloperidol",{"intervention":3080,"totalTrials":95,"cells":3082},{"EARLY_PHASE1":3083,"PHASE1":3085,"PHASE2":3087,"PHASE3":3089,"PHASE4":3091,"NA":3093},{"trials":3084,"activeCount":99},[],{"trials":3086,"activeCount":99},[],{"trials":3088,"activeCount":99},[],{"trials":3090,"activeCount":99},[],{"trials":3092,"activeCount":99},[],{"trials":3094,"activeCount":99},[3095],{"nctId":3074,"briefTitle":3075,"status":301,"phases":3096,"primaryCompletion":829,"completion":829,"start":1998,"enrollment":112,"conditions":3097,"interventions":3098},[92],[3078],[3059,3080],{"intervention":2574,"totalTrials":95,"cells":3100},{"EARLY_PHASE1":3101,"PHASE1":3103,"PHASE2":3105,"PHASE3":3107,"PHASE4":3109,"NA":3111},{"trials":3102,"activeCount":99},[],{"trials":3104,"activeCount":99},[],{"trials":3106,"activeCount":99},[],{"trials":3108,"activeCount":99},[],{"trials":3110,"activeCount":99},[],{"trials":3112,"activeCount":99},[3113],{"nctId":2567,"briefTitle":2568,"status":301,"phases":3114,"primaryCompletion":2110,"completion":2110,"start":2263,"enrollment":665,"conditions":3115,"interventions":3116},[92],[2571],[2573,2574],{"intervention":3118,"totalTrials":95,"cells":3119},"Antihypertensive Agents",{"EARLY_PHASE1":3120,"PHASE1":3122,"PHASE2":3124,"PHASE3":3126,"PHASE4":3128,"NA":3130},{"trials":3121,"activeCount":99},[],{"trials":3123,"activeCount":99},[],{"trials":3125,"activeCount":99},[],{"trials":3127,"activeCount":99},[],{"trials":3129,"activeCount":99},[],{"trials":3131,"activeCount":99},[3132],{"nctId":3133,"briefTitle":3134,"status":301,"phases":3135,"primaryCompletion":3136,"completion":3136,"start":3137,"enrollment":3138,"conditions":3139,"interventions":3141},"NCT04592783","Postpartum Hypertension, Tight vs Liberal Control Trial",[92],"2021-11-02","2020-10-19",256,[3140],"Hypertension in the Obstetric Context",[3118],{"intervention":3143,"totalTrials":95,"cells":3144},"sodium fluorescein",{"EARLY_PHASE1":3145,"PHASE1":3147,"PHASE2":3149,"PHASE3":3151,"PHASE4":3153,"NA":3155},{"trials":3146,"activeCount":99},[],{"trials":3148,"activeCount":99},[],{"trials":3150,"activeCount":99},[],{"trials":3152,"activeCount":99},[],{"trials":3154,"activeCount":99},[],{"trials":3156,"activeCount":99},[3157],{"nctId":3158,"briefTitle":3159,"status":762,"phases":3160,"primaryCompletion":3161,"completion":1776,"start":921,"enrollment":99,"conditions":3162,"interventions":3164},"NCT02757417","Intravenous Sodium Fluorescein Versus Oral Phenazopyridine for Ureteral Patency",[92],"2018-01",[3163],"Ureteral Injury",[3143,3165],"phenazopyridine",{"intervention":3165,"totalTrials":95,"cells":3167},{"EARLY_PHASE1":3168,"PHASE1":3170,"PHASE2":3172,"PHASE3":3174,"PHASE4":3176,"NA":3178},{"trials":3169,"activeCount":99},[],{"trials":3171,"activeCount":99},[],{"trials":3173,"activeCount":99},[],{"trials":3175,"activeCount":99},[],{"trials":3177,"activeCount":99},[],{"trials":3179,"activeCount":99},[3180],{"nctId":3158,"briefTitle":3159,"status":762,"phases":3181,"primaryCompletion":3161,"completion":1776,"start":921,"enrollment":99,"conditions":3182,"interventions":3183},[92],[3163],[3143,3165],{"intervention":2625,"totalTrials":95,"cells":3185},{"EARLY_PHASE1":3186,"PHASE1":3188,"PHASE2":3190,"PHASE3":3192,"PHASE4":3194,"NA":3196},{"trials":3187,"activeCount":99},[],{"trials":3189,"activeCount":99},[],{"trials":3191,"activeCount":99},[],{"trials":3193,"activeCount":99},[],{"trials":3195,"activeCount":99},[],{"trials":3197,"activeCount":99},[3198],{"nctId":2618,"briefTitle":2619,"status":301,"phases":3199,"primaryCompletion":2621,"completion":2621,"start":2622,"enrollment":180,"conditions":3200,"interventions":3201},[92],[21],[2584,2625,2626],{"intervention":2626,"totalTrials":95,"cells":3203},{"EARLY_PHASE1":3204,"PHASE1":3206,"PHASE2":3208,"PHASE3":3210,"PHASE4":3212,"NA":3214},{"trials":3205,"activeCount":99},[],{"trials":3207,"activeCount":99},[],{"trials":3209,"activeCount":99},[],{"trials":3211,"activeCount":99},[],{"trials":3213,"activeCount":99},[],{"trials":3215,"activeCount":99},[3216],{"nctId":2618,"briefTitle":2619,"status":301,"phases":3217,"primaryCompletion":2621,"completion":2621,"start":2622,"enrollment":180,"conditions":3218,"interventions":3219},[92],[21],[2584,2625,2626],{"intervention":3221,"totalTrials":95,"cells":3222},"Amevive",{"EARLY_PHASE1":3223,"PHASE1":3225,"PHASE2":3227,"PHASE3":3229,"PHASE4":3231,"NA":3233},{"trials":3224,"activeCount":99},[],{"trials":3226,"activeCount":99},[],{"trials":3228,"activeCount":99},[],{"trials":3230,"activeCount":99},[],{"trials":3232,"activeCount":99},[],{"trials":3234,"activeCount":99},[3235],{"nctId":3236,"briefTitle":3237,"status":762,"phases":3238,"primaryCompletion":2063,"completion":358,"start":1296,"enrollment":99,"conditions":3239,"interventions":3241},"NCT01433770","Alefacept in Kidney Transplant Recipients",[92],[3240],"Kidney Transplantation",[3221],{"intervention":3243,"totalTrials":95,"cells":3244},"Levetiracetam",{"EARLY_PHASE1":3245,"PHASE1":3247,"PHASE2":3249,"PHASE3":3251,"PHASE4":3253,"NA":3255},{"trials":3246,"activeCount":99},[],{"trials":3248,"activeCount":99},[],{"trials":3250,"activeCount":99},[],{"trials":3252,"activeCount":99},[],{"trials":3254,"activeCount":99},[],{"trials":3256,"activeCount":99},[3257],{"nctId":3258,"briefTitle":3259,"status":301,"phases":3260,"primaryCompletion":1612,"completion":1612,"start":3261,"enrollment":743,"conditions":3262,"interventions":3263},"NCT00221988","Effects of Keppra on Thinking, Emotions, and Balance in Elderly Healthy Volunteers",[92],"2004-03",[114],[3243],{"intervention":3265,"totalTrials":95,"cells":3266},"Mirabegron 50 MG [Myrbetriq]",{"EARLY_PHASE1":3267,"PHASE1":3269,"PHASE2":3271,"PHASE3":3273,"PHASE4":3275,"NA":3277},{"trials":3268,"activeCount":99},[],{"trials":3270,"activeCount":99},[],{"trials":3272,"activeCount":99},[],{"trials":3274,"activeCount":99},[],{"trials":3276,"activeCount":99},[],{"trials":3278,"activeCount":99},[3279],{"nctId":3280,"briefTitle":3281,"status":762,"phases":3282,"primaryCompletion":2177,"completion":3283,"start":3284,"enrollment":99,"conditions":3285,"interventions":3286},"NCT03087578","Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder",[92],"2018-09-30","2017-07-01",[1274],[3265],{"intervention":3288,"totalTrials":95,"cells":3289},"prednisolone or methylprednisolone",{"EARLY_PHASE1":3290,"PHASE1":3292,"PHASE2":3294,"PHASE3":3296,"PHASE4":3298,"NA":3300},{"trials":3291,"activeCount":99},[],{"trials":3293,"activeCount":99},[],{"trials":3295,"activeCount":99},[],{"trials":3297,"activeCount":99},[],{"trials":3299,"activeCount":99},[],{"trials":3301,"activeCount":99},[3302],{"nctId":3303,"briefTitle":3304,"status":762,"phases":3305,"enrollment":99,"conditions":3306,"interventions":3308},"NCT00798616","Steroids Helping Albuterol Responders Exclusively",[92],[3307],"Bronchiolitis",[3288],{"intervention":3310,"totalTrials":95,"cells":3311},"Vasoconstrictor Agents",{"EARLY_PHASE1":3312,"PHASE1":3314,"PHASE2":3316,"PHASE3":3318,"PHASE4":3320,"NA":3322},{"trials":3313,"activeCount":99},[],{"trials":3315,"activeCount":99},[],{"trials":3317,"activeCount":99},[],{"trials":3319,"activeCount":99},[],{"trials":3321,"activeCount":99},[],{"trials":3323,"activeCount":99},[3324],{"nctId":3325,"briefTitle":3326,"status":404,"phases":3327,"primaryCompletion":3328,"completion":3328,"start":2369,"enrollment":1407,"conditions":3329,"interventions":3331},"NCT01866657","Cerebral Oximetry in Single Lung Ventilation Thoracic Surgery",[92],"2016-11-10",[3330],"Hypoxia",[3310,3332,3333,3334],"Additional anesthesia","RBC transfusion","Increase FiO2",{"intervention":3332,"totalTrials":95,"cells":3336},{"EARLY_PHASE1":3337,"PHASE1":3339,"PHASE2":3341,"PHASE3":3343,"PHASE4":3345,"NA":3347},{"trials":3338,"activeCount":99},[],{"trials":3340,"activeCount":99},[],{"trials":3342,"activeCount":99},[],{"trials":3344,"activeCount":99},[],{"trials":3346,"activeCount":99},[],{"trials":3348,"activeCount":99},[3349],{"nctId":3325,"briefTitle":3326,"status":404,"phases":3350,"primaryCompletion":3328,"completion":3328,"start":2369,"enrollment":1407,"conditions":3351,"interventions":3352},[92],[3330],[3310,3332,3333,3334],{"intervention":3333,"totalTrials":95,"cells":3354},{"EARLY_PHASE1":3355,"PHASE1":3357,"PHASE2":3359,"PHASE3":3361,"PHASE4":3363,"NA":3365},{"trials":3356,"activeCount":99},[],{"trials":3358,"activeCount":99},[],{"trials":3360,"activeCount":99},[],{"trials":3362,"activeCount":99},[],{"trials":3364,"activeCount":99},[],{"trials":3366,"activeCount":99},[3367],{"nctId":3325,"briefTitle":3326,"status":404,"phases":3368,"primaryCompletion":3328,"completion":3328,"start":2369,"enrollment":1407,"conditions":3369,"interventions":3370},[92],[3330],[3310,3332,3333,3334],{"intervention":3334,"totalTrials":95,"cells":3372},{"EARLY_PHASE1":3373,"PHASE1":3375,"PHASE2":3377,"PHASE3":3379,"PHASE4":3381,"NA":3383},{"trials":3374,"activeCount":99},[],{"trials":3376,"activeCount":99},[],{"trials":3378,"activeCount":99},[],{"trials":3380,"activeCount":99},[],{"trials":3382,"activeCount":99},[],{"trials":3384,"activeCount":99},[3385],{"nctId":3325,"briefTitle":3326,"status":404,"phases":3386,"primaryCompletion":3328,"completion":3328,"start":2369,"enrollment":1407,"conditions":3387,"interventions":3388},[92],[3330],[3310,3332,3333,3334],{"intervention":3390,"totalTrials":95,"cells":3391},"Alfuzosin 10 mg",{"EARLY_PHASE1":3392,"PHASE1":3394,"PHASE2":3396,"PHASE3":3398,"PHASE4":3400,"NA":3402},{"trials":3393,"activeCount":99},[],{"trials":3395,"activeCount":99},[],{"trials":3397,"activeCount":99},[],{"trials":3399,"activeCount":99},[],{"trials":3401,"activeCount":99},[],{"trials":3403,"activeCount":99},[3404],{"nctId":3405,"briefTitle":3406,"status":301,"phases":3407,"primaryCompletion":3408,"completion":3408,"start":3409,"enrollment":3410,"conditions":3411,"interventions":3414},"NCT00256399","Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)",[92],"2007-05-08","2005-11",6,[3412,3413],"BPH","Erectile Dysfunction",[3390]]